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Essential medicines can save lives and improve quality of life. However, shortage of 
essential medicines has emerged as a major health system challenge in Malawi and other 
developing countries. Essential medicines are not available to one-third of the world’s population 
and half of people living in the poorest countries of Africa and Asia (WHO 2014). Shortage of 
essential medicines limits healthcare provider’s ability to treat patients and manage disease 
conditions; this has huge implications for countries’ health systems. Previous studies have 
demonstrated that shortage of some essential medicines is a chronic issue in Malawi, however, 
there are few studies on factors that contribute to the availability or shortage of essential 
medicines in Malawi’s public health facilities.  
This research explores the issue of shortages in Malawi’s public health facilities using an 
exploratory sequential mixed methods design. Using a quantitative approach, this study sought to 
determine the availability of twelve essential medicines at 131 public health facilities across 
Malawi. This was followed by a qualitative study with the aim of identifying factors that 
contributed to the availability of the medicines in Malawi’s public health facilities.  The 
qualitative study was based on interviews with eighteen key informants.  The recommendations 




This study revealed that the percent availability of essential medicines varies across the 
different categories of essential medicines, i.e., HIV/AIDS (99%), Malaria (94%), Family 
Planning (82%), other essential medicines for maternal and child health (53%). However, only  
nine (7%) of the 131 survey sites had all the twelve essential medicines in stock on the day of the 
visit.  Key factors enabling the availability of essential medicines in health facilities include 
funding; data; governance; infrastructure; procurement and human resources. According to the 
key informants, the major barriers to availability of essential medicines are lack of 
accountability, inadequate funding, poor quality data, weak governance, poor inventory 
management, inefficient procurement systems, poor product selection, and inadequate human 
resources. 
The shortage of some life-saving essential medicines in Malawi’s public health facilities 
has dire consequences for the national health system, with significant impact on the most 
vulnerable population, women and children. Based on the study findings, specific 
recommendations are provided to support the efforts of the Government of Malawi and other 
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CHAPTER 1: INTRODUCTION 
 
Essential Medicines and Global Health 
Essential medicines are those that satisfy the priority health care needs of the population. They 
are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative 
cost-effectiveness (WHO 2016). Shortage of essential medicines is a major threat to global health, 
they are not available to 33% of the world’s population and 50% of people in the poorest 
countries of Africa and Asia (WHO 2014a, 2016 a). Essential medicines save lives and improve 
health when they are available in the appropriate dosage forms, affordable, of assured quality, 
and properly used (WHO 2016a).   
In 2012, the United Nations Millennium Development Goal (MDG) Gap Task Force 
called attention to the lack of progress on improving access to and availability of essential health 
products (EHPs) such as drugs, supplies and equipment in developing countries. The Task Force 
highlighted that only 51.8% of EHPs were available in a sample of public facilities in 17 low- 
and middle-income countries (LMICs) between 2007 and 2011 (United Nations 2012).  
Gaps in supply represent one of the major factors associated with lack of drug 
availability.  Lack of medicines have a profound effect on health in various ways (Masters et al. 
2014). First, if a drug is not available at a health facility, patients will be unable to receive 
needed treatment.   Patients who do not receive proper drug treatment are likely to have worse 
outcomes. Pasquet et al. (2010) found that facility-level stock outs of antiretroviral medicines led 
to higher mortality. Second, if a facility experiences stock outs, patients may be less willing to 
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visit the facility because they do not believe they will get needed care and medicines.   Nabbuye-
Sekandi et al. (2011) found that patients’ perceptions of a health facility and their satisfaction 
with health services are directly linked with the availability of pharmaceuticals.   In addition, 
Hanson et al. (2005) found that pharmaceutical availability is a significant predictor of perceived 
quality of health facilities. These studies imply that as pharmaceutical availability decreases, 
patients’ perception of quality also decreases.   Perceived quality of a health facility can have a 
significant effect on a patient’s decision to utilize that facility. Therefore, it is important to 
maintain stocks of medicines so that people can remain confident in the health system and 
continue to utilize its services. 
Essential Medicines in Malawi 
Malawi is a landlocked country in southeastern Africa that remains one of the poorest 
countries in the world, with a Human Development Index (HDI) of 0.418, ranking 170 out of 
188 countries (UNDP 2014).  To ensure equitable access to health care, essential drugs are 
provided free of charge to patients at all public health facilities. The country spends about 30% 
of its national health budget on drugs (Lufesi et al. 2007). Shortage of essential medicines in 
Malawi’s public health facilities affect the government’s effort to provide health care to its 
growing population.   
Although the Government of Malawi (GoM) policy is to provide free health care services 
and essential medicines to patients in all public health facilities, stock outs of essential medicines 
remain a challenge. Mazengera (2012) found that only nine percent of public hospitals and 
clinics in Malawi had adequate supplies of all drugs and supplies in the essential healthcare 
package. A study of the availability of essential medicines among community health workers 
(CHWs) in Ethiopia, Malawi and Rwanda showed a shortage of essential medicines in every 
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country, with more than half of CHWs stocked out of at least one tracer product on the day of 
assessment (Chandani et al. 2012). The tracer product is one of the essential medicines 
commonly used by community health workers in this study, generally, a tracer product is used to 
describe a category of medicine that is commonly used to treat a particular health condition.   For 
example, artemether/lumefantrine (CoartemÒ) used for treatment of malaria.  
Several factors have been found to contribute to the shortage of essential medicines in 
public health systems.   These include: (i) inadequate financing; (ii) regulatory problems; (iii) 
lengthy procurement processes; (iv) lack of incentives for maintaining sufficient stock levels; (v) 
poor logistics management (e.g., forecasting, distribution, information technology [IT] systems); 
(vi) corruption; and (vii) lack of qualified health workers to manage the supply chain (Bigdeli 
2013; Chandani et al. 2012; Liu et al. 2015; Lufesi 2007; Lubinga et al. 2014; Mazengera 2012; 
Mueller 2011). Most of these factors are applicable to Malawi; however, there is limited 
evidence in current studies of the relative importance of each of these factors in the Malawi 
context.  
The GoM Health Sector Strategic Plan 2011-2016, prioritized availability of essential 
medicines and medical supplies as a key intervention area, and identified shortage of essential 
medicines as a key risk that might hinder the MOH and its stakeholders in the implementation of 
the plan. MOH assigned shortage of essential medicines the highest rating on a high-risk scale 
ranging from low to high. A low rating represents a risk factor that might not significantly 
impact the plan, while a high-risk factor has a significant impact on the plan (MOH 2011). 
Availability of essential medicines is a very sensitive political and social issue in Malawi, as is 
the case in many other countries. For instance, stock outs of medicines or drug theft from public 
health facilities are often featured in national newspapers and editorial columns.    
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Studies assessing the availability of essential medicines in Malawi and factors affecting 
availability can help shape policies and interventions to improve availability. To date, studies to 
assess the availability of essential medicines and the factors associated with their availability are 
very limited. The objective of this study is to assess the availability of essential medicines in 
Malawi’s public health facilities and identify the factors contributing to their availability 
(enablers) or shortage (barriers).  
Conceptual Model: 
 
The John Snow Inc. logistics cycle (Figure 1) is a relevant model for this study.  It has 
been used widely to ensure availability of health commodities in a public health system. It also 
serves as a theoretical framework for understanding the activities that affect the availability of 
medicines in the system. The goal of a health logistics system is much broader than simply 
making sure that a product safely arrives at its destination. Ultimately, the goal of every public 
health logistics system is to help ensure that every customer has commodity security. 
Commodity security exists when every person can obtain and use quality essential health 
supplies whenever they are needed (USAID|DELIVER Project 2011). 
A functional logistics system supports consistent availability of medicines in the supply 
system by ensuring the “six rights”: the RIGHT goods in the RIGHT quantities in the RIGHT 
condition delivered to the RIGHT place at the RIGHT time for the RIGHT cost 




Figure 1: Conceptual Framework- The Logistics Cycle  
Source: USAID | DELIVER PROJECT, Task Order 1. 2011. The Logistics Handbook: A Practical Guide 
for the Supply Chain Management of Health Commodities. Arlington, Va.: USAID | DELIVER 
PROJECT, Task Order 1. 
The four activities in boxes around the cycle – product selection, quantification and 
procurement, inventory management, and serving customers -- represent actions that must be 
taken to ensure availability of medicines. The central box represents core management support 
functions that contribute to availability of medicines in a public system.  This includes such 
activities as data collection, reporting and use, finance and budgeting, human resources, 
supervision and oversight, and monitoring and evaluation. 
The section below describes the role of these activities in the context of essential 
medicines: 
Serving Customers: The overall goal of a functioning logistics system is to ensure 
availability of health commodities at service delivery points to meet patients’ need. I applied this 
context to my study and determined the extent to which selected essential medicines (e.g., 
antibiotics, HIV/AIDS medicines, Malaria and Family Planning medicines) were available to 
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clients at study sites on the day of visit.  The day of visit refers to the day in which the researcher 
visited and determined availability. 
Product selection: This is a critical step in public health programs that focuses on the 
selection of medicines and health products based on the WHO Model List, national treatment 
guidelines, or expert panel recommendations. Products selected for use will impact the logistics 
system, so logistics requirements must be considered during product selection 
(USAID|DELIVER 2011). This was a relevant consideration for this study. It enabled me to 
describe how product selection contributes to the availability or shortage of essential medicines 
at the study sites. 
Quantification and Procurement: This is the process of estimating the quantity and cost 
of the products required for a specific health program (or service), ensuring an uninterrupted 
supply for the program, and determining when the products should be procured and distributed 
(USAID|DELIVER 2011). In Malawi, essential medicines are procured from different 
stakeholders, and the logistics for procurement may vary according to the medicine.  This in turn 
may affect availability or shortage of the targeted medicines at study sites.  This concept was 
very useful in demonstrating the impact of quantification on availability of essential medicines 
through key interviews with respondents. 
Inventory management, Storage and Distribution: These activities include efforts to 
ensure proper recording and management of medicines in various storage locations in-country. 
These activities include the distribution model from the central warehouses to public health 
facilities. This study described how the various inventory management, storage and distribution 
methods affected the availability of essential medicines in Malawi’s public health facilities. 
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  Logistics Management Information Systems (LMIS): The LMIS is an information 
management system that provides data on each activity in the logistics cycle; it provides 
managers with critical data for decision making and the routine management of essential 
medicines in the system. In Malawi, public health facilities collect and report data on medicines 
dispensed to clients and stock balances every month to central level managers through paper- 
based and electronic systems. This factor was very relevant in describing how the availability, 
quality and timeliness of LMIS data contributed to the availability of essential medicines in 
Malawi’s public health facilities. 
Pipeline Monitoring: To ensure availability of medicines as service delivery points, 
supply chain managers need to constantly monitor the medicines as they move from 
manufacturers or vendors through a chain of storage facilities and transportation links to the 
service delivery points. Inadequate monitoring of the supply pipeline can impact on timely 
delivery and availability of essential medicines in both public and private health system, this 
consideration was very helpful in understanding key informants’ view on factors affecting the 
availability of essential medicines in Malawi. 
Organization and Staffing: A logistics system can only work if well-trained, efficient 
staff monitor stock levels, place orders, and provide products to clients. Ideally, to carry out 
logistics activities, health programs assign staff with the appropriate competencies. In fact, some 
countries have established national logistics management units that analyze logistics data and 
provide feedback throughout the system (USAID|DELIVER 2011). This study described how 
organization and staffing plans influenced the availability or shortage of essential medicines at 
targeted study sites.   
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Budgeting: Allocation and management of finances affect all activities in the logistics 
cycle and contribute to the availability of essential medicines in the system. Managers need to 
ensure that funds are available to procure required medicines, and to cover the costs of storage 
and distribution to health facilities. This concept informed my analysis of stakeholders’ insights 
on how financial resources contribute to the availability or shortage of tracer essential medicines.   
Supervision: Staff supervision is a key function necessary to ensure that the logistics 
system runs smoothly and can anticipate needed changes. Routine, effective supervision, coupled 
with on-the-job training in logistics, helps to prevent and resolve supply problems and human 
resource constraints (USAID|DELIVER 2011).  In line with this conceptual framework, I 
described how supply chain related supervision contributes to the shortage or availability of 
essential medicines in the system. 
Monitoring and Evaluation (M&E): Through regular monitoring and periodic 
evaluation, managers can determine progress and gaps in the essential medicines supply plan, 
including potential risks that can contribute to shortage of essential medicines in the system. 
Based on my qualitative study results, I described the importance of regular monitoring of the 
supply chain and how it can contribute to the availability of essential medicines in public health 
facilities. 
Quality Monitoring: This refers to the quality of the product and work done throughout 
the logistics cycle. To ensure availability of essential medicines, managers and health facility 
staff must ensure strict adherence to procurement and national supply chain guidelines. This 
study described how quality monitoring activities contribute to the availability of essential 
medicines in public health facilities.   
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All the actions described in the logistics cycle operate within a policy framework that is set by 
the organization or government responsible for the health care system. 
The logistics cycle served as a conceptual model that informed my analysis of barriers 
and enablers associated with the availability of essential medicines in Malawi.  I also identified 
other enablers or barriers that were not part of the logistics cycle, especially context-driven 
factors that are peculiar to Malawi’s public health system.  These include, for example 
governance and infrastructure. 
The various components of the logistics cycle were used to generate qualitative research 
questions on barriers and enablers that affected the availability of essential medicines in Malawi 
in this study.  It also informed my recommendations on actions and policies that will contribute 
to increased availability of essential medicines in my plan for change (Chapter 6). 
I conducted a literature review as part of my study methods. The main aim of my 
literature review is to describe past studies of essential medicines availability and explore how I 
can leverage these findings to explain and interpret my study results. Although this study is 
primarily focused on Malawi, my literature review includes studies on the availability of 
essential medicines in other SSA countries and LMICs. The comparative review provides multi-
country perspectives on issues related to availability of essential medicines and how Malawi’s 
situation compares with other countries’ context and experiences. Table 1 provides a summary of 








Essential medicines are those that satisfy the priority health care needs of the population. 
They are selected with due regard to public health relevance, evidence on efficacy and 
safety, and comparative cost-effectiveness (WHO 2016a) 
 
Access 
Is defined as having medicines continuously available and affordable at public or 
private health facilities or medicine outlets that are within one hour’s walk from 
the homes of the population (WHO 2010) 
 
Availability 
Medicine is in stock, unexpired and in good condition, on day of inspection visit 
(Chandani et al. 2012). 
Health 
facilities 
Health facilities include hospitals, clinics, outpatient care centers, and specialized care 












Category of health workers who provide health education and referrals for a wide 
range of services, and provide support and assistance to communities, families 
and individuals with preventive health measures and gaining access to appropriate 
curative health and social services. They create a bridge between providers of 
health, social and community services and communities that may have difficulty 
in accessing these services (WHO 2018) 
Facilitator 
 
A person, organization or other factor that helps to increase the availability of essential 







The complete absence of a medicine, health product or vaccine at the point of service 




A means or agent by which certain substances or structures can be identified or followed 







Research Question and Aims 
Research question: How can the availability of essential medicines in Malawi’s public health 
facilities be improved? 
Aims: (1) To determine the current availability of essential medicines in Malawi’s public health 
facilities.  
 (2) To identify factors that contribute to and impede the availability of essential medicines in 





















CHAPTER 2: LITERATURE REVIEW 
 
I reviewed the literature using the Preferred Reporting Items for Systematic reviews and 
Meta-Analysis (PRISMA) checklist and flow diagram (Liberati et al. 2009). I identified relevant 
articles following a search of four databases: Global Health, Scopus, Embase and PubMed 
Central.  
I initiated the literature search on March 5, 2017 using the following search terms 
(availability OR access) AND (essential medicines OR essential health services) AND (Malawi 
OR sub-Saharan Africa OR LMIC) 
Table 2: Search terms 
 
Availability  AND Essential 
Medicines 
AND Malawi  
OR  OR  OR 
Access   Essential 
Health 
Services 
 Sub-Saharan Africa 
 
   OR  
   Malawi Hospitals  
   OR  
   LMIC 
  
Additional searches through “snowball” approaches (a nonprobability sampling 
technique) and exploring other bodies of literature from relevant publications’ citation list 
yielded additional articles.  I also identified “grey literature” articles (i.e., not peer-reviewed) 
from the WHO website and through Google searches.  
I focused on studies published in the ten-year period 2007 and 2016 in the four 
bibliographic search engines. The goal was to identify studies that are related to availability of 
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essential medicines; describe factors contributing to or impeding the availability of essential 
medicines; and highlight the importance of essential medicines in global health. For final review, 
I exported into Microsoft Excel studies identified from the literature search, and refined the list 
through de-duplication, screening of titles, and reviewing abstracts and identification of studies. 
Each phase was completed in a separate tab in the Excel file. 
At the end of the search, I identified relevant articles for final review based on the 
following inclusion criteria: studies focused on essential medicines in Malawi or a medicine 
classified as essential by WHO; and studies published within the past 10 years (2007-2016) and 
conducted in Malawi, Sub-Saharan Africa or other LMICs. I imported the full text of articles that 
met these criteria into Mendeley, a reference manager.  I then used these articles for further 
analysis.   
 I excluded studies conducted in developed countries, as well as studies with the 
following characteristics:   studies focused on medicines not classified as essential medicines by 
WHO; studies characterized as systematic reviews; and studies not published in English; and 
studies using an unclear methodology. 
I compiled full text articles that met the inclusion criteria in an abstraction form 
(Appendix A) to extract the following information for further review: article title, journal, author, 
year of publication, study design, population studied, results describing the availability of 
essentials medicines and barriers and enablers, and study limitations. 
Results: 
The literature search yielded 367 studies using the PRISMA checklist, including 124 
from Global Health, 112 from Scopus, 77 from Embase, and 47 from PubMed Central. I 
identified seven studies from other sources, three from the grey literature, and four through 
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snowballing. After adjusting for duplicates, 176 remained.  Of these, I excluded 67 articles with 
irrelevant titles, leaving 109 articles for abstract review. I eliminated eighty-five studies after the 
abstract review based on my inclusion and exclusion criteria detailed above.  I used the 
remaining 24 studies for further review.  
I completed a full text review of these 24 studies, and subsequently eliminated seven for 
the following reasons:  they (1) were a conference presentation (n=1); (2) did not focus on 
essential medicines (n=3); (3) were an incomplete article (n=2); or (4) were an uncompleted 
study (n=1). The remaining 17 studies met eligibility criteria and were included in the literature 
review (Figure 2). 
Study Characteristics 
 
All the studies reviewed (n=17) focused on issues related to the availability of essential 
medicines and factors contributing to their availability or stock outs. Five studies were conducted 
in Malawi, eight in other SSA countries, and four in other LMICs. Seven studies were survey-
based using quantitative methods, five used both quantitative and qualitative methods, two were 
WHO technical reports on factors affecting the availability of essential medicines in LMICs, one 
was a qualitative study, and two were from a grey literature source – Mazengera 2012 and MOH 
2011 respectively. Five of the 17 studies provided insights on the availability of essential 
medicines and factors that contributed to shortage or availability. 
Availability of essential medicines 
Of the 17 studies analyzed, 14 reported shortages of essential medicines in their study 
setting, with the availability of essential medicines ranging from seven to eighty percent (Babar 
et al. 2013; Bissell et al. 2016; Chandani et al. 2012; Leung et al. 2016; Liu et al. 2015; Lufesi et 
al. 2007; Lungu et al. 2016; Mazengera 2012; Masters et al. 2014; Mendis et al. 2007; Mueller et 
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al. 2011; Robertson et al. 2009; Wagenaar et al. 2014; WHO 2016). Public health facilities with 
lower availability had fewer essential medicines and those that with higher percentages had most 
essential medicines. 
The quantitative study by Chandani et al. (2012) revealed shortages of essential 
medicines among CHWs in Ethiopia Malawi, and Rwanda.   More than half of CHWs were 
stocked out of at least one tracer product (amoxicillin, artemether/lumefantrine, Cotrimoxazole, 
oral rehydration salts, ready-to-use-therapeutic food, and Zinc) on the day of assessment.  
Rwanda had the highest rating, where 61 percent of essential medicines were available, and 
Ethiopia ranked lowest at seven percent1.  In Malawi, 29 percent of essential medicines were 
available among CHWs.  Artemether/lumefantrine, an antimalarial medicine, was the 
Community Case Management (CCM) product most likely to be out of stock. 
Masters et al. (2014) conducted a quantitative study of pharmaceutical availability across 
levels of care in Ghana, Kenya and Uganda. Their study revealed varying level of availability in 
essential medicines at selected health facilities. They measured availability of essential 
medicines in 659 health facilities across three countries and reported an average stock-out rate of 
25 percent, meaning health facilities in these countries lacked one out every four essential 
medicines required by patients on the day of the survey. 
Lungu et al. (2016) completed a qualitative and quantitative case study on healthcare 
seeking practices and barriers to accessing under-five child health services in urban slums in 
Malawi.  They found that only nine per cent of public health facilities (54 out of 585) in Malawi 
provided the full Essential Health Package (EHP) list of essential drugs. Their study focused 
                                               
1 The percentage availability in Ethiopia, Malawi and Rwanda might have changed significantly 




largely on public health facilities and revealed inadequate supply of medicines and other medical 
supplies as a recurring theme in focus group discussions (FGDs) and key informant interviews 
(KIIs) at both policy and service delivery levels.   
Another quantitative and qualitative survey in Malawi by Mueller et al. (2011) focused 
on constraints to implementing the EHP. The study revealed that 27 percent of health facility 
managers (n =136) considered Cotrimoxazole (medicine used for treatment of acute respiratory 
tract and other infections) to be of sufficient supply in their respective facility, 60 percent 
reported insufficient stock, while 13 percent of the facilities were completely out of stock at the 
time of the survey. The situation for oral antibiotics benzathine-penicillin and erythromycin was 
even more critical with only 24 percent and 22 percent of health centers having sufficient 
quantities in stock, and 13 percent and 20 percent being entirely out of stock, respectively.    
Enablers: Factors contributing to availability of essential medicines 
 
Although 14 of the 17 studies identified shortages of essential medicines at varying levels 
in their study settings, only six of the 14 provided insights on factors that might have contributed 
to the availability of medicines.   
In a quantitative study of pharmaceutical availability across levels of care in Ghana, 
Kenya and Uganda, Masters et al. (2014) revealed that the presence of a utility vehicle at public 
health facilities can contribute to increased availability of essential medicines in hospitals and 
clinics. In Uganda, the presence of a vehicle was associated with fewer stock outs for all drugs, 
including essential medicines. In Ghana and Kenya, the results were similar, with presence of a 
vehicle associated with fewer stock outs. However, the association was only significant for 
essential medicines. The study also revealed that health facilities receiving medicines from the 
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MOH and from private pharmacy suppliers tended to have a lower number of stock outs than 
facilities receiving supplies from only the MOH.  
  Masters et al. (2014) found that the existence of a functional laboratory in public health 
facilities is also associated with greater availability of essential medicines. Having a laboratory in 
the facility was significantly associated with reduced essential medicine stock outs, possibly 
suggesting that more advanced facilities are able to test and subsequently treat only health 
conditions confirmed by a laboratory test, which would drive down unnecessary use of 
pharmaceuticals. 
A multi-country quantitative survey on the availability and affordability of selected 
essential medicines for chronic diseases in six LMICs (including Malawi) revealed the 
substantial role that international donors play in the supply of drugs to the public sector in low-
income countries (Mendis et al. 2007). In a qualitative and quantitative study conducted to 
determine whether drug availability in Malawian central hospitals improved after the conversion 
of Central Medical Stores (CMSs) to a trust (CMST), results showed an improvement of drug 
availability at both the CMST and Kamuzu Central Hospital after the change from CMS to a 
Trust (from a government department to a semi-autonomous government organization) (Khuluza 
et al. 2014). 
A study on deficient supplies of drugs for life threatening diseases in Malawi revealed 
that the supply of anti-malarial drugs was somewhat better than the supply of drugs used to treat 
pneumonia (Lufesi et al. 2007). From the authors’ perspective, donations contributed to 
improving the availability of certain essential medicines.   Drugs for treating malaria, HIV/AIDS, 
and tuberculosis had received special attention from governments and international 
organizations, including the Global Fund for HIV/AIDS, Tuberculosis and Malaria (GFATM), 
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and the Roll Back Malaria Global Partnership. 
According to WHO (2016c), improvements in the supply of essential medicines may also 
be attributed to publications on global approaches to addressing shortages of essential medicines 
in health systems, effective stakeholder discussion, effective management of supply chains, and 
discussion of ethical medicine use and fair pricing strategies. 
Barriers: Factors contributing to shortage of essential medicines  
 
Twelve out of the 17 studies reviewed identified factors contributing to the shortage of 
essential medicines. Bigdeli et al. (2013) found that barriers to the availability of essential 
medicines are widespread, multiple and complex. In their study of stock outs of essential health 
products in Mozambique (a country neighboring Malawi), Wagenaar et al. (2014) attributed 
distance from the district warehouse as the factor most strongly related to medicine stock outs at 
the facility level: For each 10 kilometer increase in distance, the rate of stock outs increased by 
19 percent (95 percent confidence interval [CI]: 12-26%). Inadequate human resources at public 
health facilities also contributed to stock outs of essential medicines. 
 In Malawi, Mueller et al. (2011) explored constraints to effective implementation of the 
essential package, including essential medicines.  Using qualitative and quantitative methods, 
they attributed shortages of essential medicines to:  (1) cumbersome and long World Bank 
procurement procedures; (2) insufficient qualified staff to quantify adequately their need for 
essential medicines; (3) high staff turnover; (4) poor warehousing and lack of space leading to 
drugs being delivered from central or regional warehouses to health facilities too quickly and not 
based on need or request; (5) poor inventory systems; and (6) lack of capital funds to procure 
sufficient drugs in advance to accommodate  additional need and spoilage (buffer stock). They 
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concluded that Central Medical Stores, the national procurement agency for public health 
medicines, appeared to take on a drug rationing role in response to these problems. 
A quantitative study by Lufesi (2007) on supply deficiencies of drugs for life threatening 
diseases in Malawi attributed shortage of essential medicines in public health facilities to 
insufficient deliveries from the regional medical store, inaccurate inventory management, uneven 
distribution of drugs among health centers, and lack of training among health facility staff. 
Other studies attributed the shortage of essential medicines to lack of product availability at 
resupply points; lack of supply chain knowledge and capacity; unavailability of appropriate 
transport; outdated essential medicines lists; inefficient procurement systems; and the status of 
central medicine stores as a government department (Chandani et al. 2012, Babar et al. 2013, 
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The aim of my literature review was to synthesize the evidence on availability of 
essential medicines in Malawi’s public health facilities and factors contributing to their 
availability (enablers) or shortages (barriers). My findings indicate that shortage of essential 
medicines is a health system challenge in Malawi and other LMICs. Shortages are due to 
multiple factors depending on the country context. The findings have significant implications for 
policy makers and health care providers, as discussed below. 
Availability of essential medicines 
The breadth of findings from this review suggests that essential medicines are not 
consistently available at health facilities in Malawi, other SSA countries, and other LMICs. The 
studies reviewed also highlight the heterogeneous nature of medicine availability across the 
tertiary, secondary and primary public health facilities. The shortage of essential medicines in 
hospitals is a significant threat to public health. Essential medicines are lifesaving health 
products and serve as a critical intervention for prevention and treatment. Lack of essential 
medicines may result in poor health outcomes, including death.   
When essential medicines are not available at public health facilities, the patients may be 
forced to buy their medications from the private sector or forgo treatment if they are unable to 
obtain medications elsewhere. Shortage of essential medicines can have a huge negative impact 
on Malawi, given its poor economic situation. Very few patients are able to buy medicines as 
out-of-pocket expenses when they are not available at GoM hospitals or clinics. Moreover, 
alternative healthcare financing mechanisms such as health insurance are very limited. Since 
essential medicines are used to treat multiple health conditions, the shortage of essential 
medicines can have a major impact on the population, regardless of age, gender or location. 
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Women and children represent the most vulnerable populations.   Policymakers and health 
program managers must consistently prioritize actions that will increase the availability of 
essential medicines at their health facilities, especially in Malawi, where most people rely on 
public health facilities for their health care needs. 
Although this literature review identified studies related to the availability of essential 
medicines in LMICs, including Malawi, only four of 17 studies focused solely on Malawi.   This 
underscores the need for more research in this critical aspect of Malawi’s health system. 
Factors contributing to availability of essential medicines (enablers) 
The literature review suggests a considerable number of factors that can contribute to the 
availability of essential medicines in public health facilities in Malawi and other developing 
countries. Enabling factors include a standardized system for drug procurement, political 
commitment, training of health workers on logistics management, rational use of medicines for 
the proper purpose, multiple source of drug supplies (public and private vendors), diversified 
donors, and the presence of a transportation vehicle and laboratory at a health facility. Some of 
the factors, though not specific to Malawi, might be applicable to the Malawi context given the 
similar nature of health systems in SSA countries. The potential impact of each of these factors is 
detailed below. 
Standardized procurement systems:  
The review indicates that efforts to standardize drug procurement processes can increase 
the availability of essential medicines. Such efforts include compliance with policies and 
standard operating procedures for medicine procurement. For instance, a weak procurement 
system can result in delays in the supply of medicines by suppliers due to ambiguous product 
specifications. Medicines are specialized commodities, so procurement teams are required to 
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procure quality assured medicines at the most appropriate cost in a timely manner. Moreover, 
essential medicines procurement is a multidisciplinary process; clinicians, health program 
managers, supply chain management teams, and health facilities must all have a common 
understanding of the procurement process.    Otherwise, delays from any stakeholder can impact 
the procurement time frame and availability of medicines at public health facilities.    
Political commitment:   
Evidence suggests that good governance and political commitment can contribute to the 
availability of essential medicines.   Lack of political commitment by government can undermine 
efforts to promote consistent availability of essential medicines. Without strong political 
commitment, sufficient funds may not be allocated for procurement of essential medicines.  
Health worker training and rational use of medicines:  
The review also suggested that training of health workers can promote effective 
management of essential medicines and increase their availability. Health workers need basic 
skills to quantify requirements for essential medicines, procure the right medications, and ensure 
proper inventory management and dispensing to patients. Health workers trained on proper 
management of essential medicines may be more likely to order the right medicines, ensure 
proper record keeping, and promote the rational use of medicines. Moreover, they may be better 
able to assess stock-out threats and avert shortages of essential medicines. Inadequate human 
resources with health and supply chain management skills are major health system barriers in 
Malawi. Further studies are needed to better understand the impact of human resource shortages 





Multiple drug supply sources:  
Evidence from the review suggests that public health facilities with multiple sources of 
drug supplies are likely to achieve higher levels of availability of essential medicines compared 
to those that depend on only government sources. Public health facilities with multiple sources of 
supply can readily seek alternative solutions when essential medicines are not available from the 
usual source, the government system. Public health facilities with only one supply source are at 
risk of stock-out when their source does not have needed medicines in stock. Evidence 
underscores the need for governments to develop policies that will enable public health 
authorities to procure medicines from private pharmacies as a contingency measure, instead of 
relying on centralized procurement for all their supplies. 
Diversified donors:  
This literature review revealed that essential medicines donated by international or local 
donors can contribute to the availability of essential medicines in Malawi and other LMICs. 
Given the paucity of financial resources for health, most SSA countries are unable to fund their 
entire essential medicines requirement.   In such situations, donations have helped countries meet 
their essential medicines requirements. Mendis et al (2017) provided insights on how donations 
had contributed to the availability and affordability of selected essential medicines for chronic 
diseases in six low- and middle-income countries, including Malawi. 
Transportation and laboratory: 
  The review also generated evidence on the impact of transportation vehicles and a 
laboratory at a public health facility on essential medicines availability. Compared with health 
facilities that do not have vehicles, facilities with vehicles have a greater ability to visit district or 
central warehouses for resupplies when they are stocked out or have shortages of essential 
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medicines. Similarly, presence of a functional clinical laboratory in a public health facility can 
contribute to the availability of essential medicines. Clinicians who practice at clinics with a 
functional laboratory are more likely to confirm patients’ disease conditions and treat clients 
based on need. In the absence of a functional laboratory, clinicians may be more likely to treat 
clients presumptively (based on symptoms without proper diagnosis) and with medications that 
might not be applicable to the patient’s condition.  Such practices contribute to the irrational use 
and waste of essential medicines. 
 Factors contributing to shortage of essential medicines (barriers) 
This literature review generated evidence on factors that contribute to the shortage of 
essential medicines in Malawi and similar countries. The barriers include inadequate funds for 
medicines procurement, weak supply chain management systems unreliable data, pilferage, 
inadequate infrastructure, and a shortage of human resources for medicine management. These 
factors contribute to the shortage of medicines in different ways as described below. 
Inadequate funding: 
Inadequate funding for essential medicines procurement limits countries’ capacity to 
procure sufficient essential medicines for their health programs.  Governments must often seek 
alternative funding mechanisms for essential medicines to address shortages.   
Weak supply chain management systems: 
 The review underscored the impact of effective supply chain management on the 
availability of essential medicines. Weak supply chain management practices such as poor 
quantification, inefficient procurement, and inadequate warehousing and distribution systems 
may result in the shortage of essential medicines. Weak supply chain management systems can 
lead to: shortages of essential medicines due to misprocurement; ad hoc emergency 
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procurements (relatively more expensive than planned procurement); expiry of medicines 
resulting from poor stock monitoring; and loss of essential medicines due to poor handling and 
storage conditions. 
Inadequate human resources and infrastructure: 
The review also highlighted the impact of inadequate human resources and infrastructure 
on the availability of essential medicines. Health workers play a critical role in managing health 
products and providing health services. The shortage of health workers undermines a health 
system’s capacity to plan for, manage, and provide essential medicines. The procurement and 
management of essential medicines requires careful planning and monitoring. It may be difficult 
for public health facilities to quantify their essential medicines’ requirements and place timely 
requisitions for supplies if they do not have skilled workers that are fully responsible for their 
essential medicines program. Similarly, inadequate infrastructure may contribute to the shortage 
of essential medicines due to poor storage conditions. Most medicines need controlled 
temperature storage conditions, and inadequate infrastructure can result in storage of medicines 
in substandard conditions and expose them to damage.  Such incidents contribute to the shortage 
of essential medicines.  
Pilferage: 
 The Malawi Health Sector Strategic Plan (2011-2016) identified pilferage as a major 
problem contributing to the shortage of essential medicines (MOH 2011). Further studies are 
required to understand factors contributing to pilferage, its impact, and the magnitude of the 
problem. 
Although some studies have examined factors affecting the availability of essential 
medicines, evidence from this review suggests the barriers to availability of essential medicines 
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are context-specific and there is no “one-size-fits-all” approach to address them. To address these 
barriers, policy makers need to identify ways to fully assess factors affecting the availability of 
essential medicines in their settings.  Such assessments can reveal root causes and provide 




The studies reviewed provided useful insights for my study in terms of scope and 
methodology; they applied either qualitative or quantitative research methods (or both). Four of 
the 17 studies employed mixed methods to assess the availability of essential medicines and 
factors contributing to availability or shortage.  The mixed method approach is advantageous for 
this kind of study because it enables researchers to quantify the availability of essential 
medicines and assess positive and negative contributing factors.  While quantitative methods 
allow researchers to determine the level of availability of essential medicines in a setting, they 
may not provide a full understanding of factors that might have contributed to their availability 
or shortage.   Hence, to better understand the reasons behind drug shortages, there is a need for 
qualitative methods to accompany quantitative methods.    
Limitations of Review 
 
This literature review has several limitations that might affect the validity and 
generalizability of my findings. First, some of the studies were based on a cross-sectional “spot” 
survey which might not reflect the true picture of availability of medicines in the study setting.  It 
is possible that some clinics may have run out of supplies on the day of the survey and might be 
scheduled to receive resupplies that day. Consequently, I will be unable to synthesize availability 
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in terms of time frame (days, weeks or months). Further studies are needed to assess availability 
of essential medicines over a broader time frame rather than at a single point. 
Second, the studies included in the review used different metrics to measure availability 
of essential medicines.  For instance, some studies measured the percentage of essential 
medicines that were available in the health facility while others measured the percentage of 
health facilities that were stocked out of essential medicines during the survey.  Such variation in 
metrics presents a significant challenge in comparing findings across settings. 
Third, because the barriers to availability of essential medicines are context specific, it 
was difficult to pinpoint the major factors that contribute to availability or shortage of essential 
medicines across study settings.  Consequently, the factors identified in these studies were not 
weighted or rated but mentioned broadly as enablers or barriers. Subsequent researchers should 
explore ways to rank applicable barriers in their study settings through quantitative or qualitative 
methods, or both. 
Fourth, the studies reviewed focused on different classes of essential medicines, so it was 
difficult to compare findings across countries given the variation in targeted essential medicines. 
Considering the high burden of preventable diseases in SSA countries, future researchers should 
explore options to access availability of essential medicines used for treatment of high impact 
preventable diseases. For instance, in Malawi, HIV/AIDS, tuberculosis and malaria are major 
threats to public health, so studies on availability of essential medicines for these conditions may 
contribute to efforts to increase their availability and improve public health. 
Fifth, I excluded studies published in languages other than English.  Consequently, my 
review did not include studies from non-English speaking countries in SSAs and LMICs. 
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Findings from non-English speaking SSA countries, e.g. Senegal and Cote d’Ivoire, could have 
enriched the information from this literature review. 
Conclusion:  
 
The goal of this literature review was to assess the availability of essential medicines in 
Malawi’s public health facilities and factors contributing to the shortage or availability of 
essential medicines. The studies revealed shortages of life saving essential medicines in Malawi 
and LMICs, which has major implications for morbidity and mortality. GoM, international 
organizations and stakeholders must prioritize efforts to increase the availability of essential 
medicines in public health facilities.  The literature suggests the following recommendations for 
the role of governments:  strengthen health supply chains; provide utility vehicles for health 
facilities to facilitate collection of essential medicines from government medical stores or 
alternative sources; ensure accountability and good governance at levels; train health care 
workers on effective management of essential medicines; and increase budgets for the 
procurement of essential medicines and strengthen health systems to ensure consistent 
availability of essential medicines in public health facilities. Future studies should assess the 
availability of essential medicines in Malawi in a holistic manner by identifying factors that 












CHAPTER 3: METHODOLOGY 
 
My study had two central aims: to determine the availability of essential medicines in 
selected public health facilities in Malawi, and to identify factors contributing to or impeding the 
availability of essential medicines in public health facilities. Using a mixed method design, I 
used an explanatory sequential mixed method (Figure 3), as described by Creswell (2014) to 





Figure 3: Exploratory sequential mixed method design. Reprinted from Research Design: 
Qualitative, Quantitative, and Mixed Methods Approaches (4th ed.), by J.W. Creswell. 2014, 
Thousand Oaks, California: SAGE Publications, Inc. 
  The method consists of two distinct phases: a quantitative study, followed by a qualitative 
study. I adopted the WHO/HAI methodology to survey the availability of essential medicines at 
study sites (WHO & HAI 2008). It is usually not feasible to collect data from all public health 
facilities in a country within a limited time.  Therefore, this study was conducted in 131 of the 
approximately 640 public health facilities across the three regions of Malawi: north, central and 
south.  Sites were selected using a stratified sampling method. Health facilities in Malawi’s 
public health facilities data base (about 640 facilities) were divided into subgroups (strata) 
   Phase 1   Phase 2 
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according to region, district, service level (primary, secondary or tertiary healthcare), and rural or 
urban location.  
In first phase of the study I conducted a quantitative survey on availability of twelve 
commonly used essential medicines for management of HIV/AIDS, malaria, family planning, 
maternal health, pneumonia and other common infections (Table 3). The essential medicines in 
Table 3 are the most frequently used medicines for managing the specific health conditions as 
recommended in the National Standard Treatment Guideline (MOH 2015). The HIV/AIDS, 
malaria, and family planning medicines are predominantly procured by donors in Malawi, GoM 
occasionally procures malaria medicines and Depo-Provera, one of the family planning 
medicines, based on availability of funds. However, the GoM is solely responsible for the 
procurement of other essential medicines- Dispersible Amoxicillin, Oxytocin injection, and Oral 
Rehydration Salts. Moreover, the selected medicines have potential impact on health conditions 
that contribute to the disease burden and affect contraceptive services in Malawi. 
The quantitative phase was followed by a qualitative study involving key informant 
interviews with the following stakeholders: policy makers, donors, program managers, central 
and district hospital pharmacists. The overall intent of this design was to use qualitative data to 
inform and explain the quantitative results (Creswell 2014).   Stakeholders were purposefully 
selected for the study. The advantage of the sequential study was two-fold.  First, the quantitative 
phase enabled me to generate data on the availability of essential medicines across study sites. 
The results of my quantitative study were helpful in shaping my probing questions in the 
qualitative phase. I also solicited stakeholders’ perspectives on factors that contributed to the 
availability or shortage of essential medicines observed in the quantitative phase.  My goal was 
to provide an informed explanation for the results obtained in phase one.   
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Additionally, I collected data about the public health facilities surveyed (tertiary, 
secondary, primary, urban versus rural, region, and its size), and data on key informants 
(occupation/position, role or other demographics). 
Table 3: List of selected essential medicines for specific health conditions 
   
S/No Category Medicine 
1 HIV/AIDS Dolutegravir/Lamivudine/Tenofovir Disoproxil 
Fumarate 50 mg/300 mg/300 mg Tablet 
(Regimen 13A) 
2 HIV/AIDS Zidovudine/Lamivudine/Nevirapine 
60mg/30mg/50mg Tablet (Regimen 2P) 
3 Malaria Artemether 20mg-Lumefanthrine 120 mg Tablet 
(LA1x6 tab) 
4 Malaria Artemether 20mg-Lumefanthrine 120 mg Tablet 
(LA 2x6 tab) 
5 Malaria Artemether 20mg-Lumefanthrine 120 mg Tablet 
(LA 3x6 tab) 
6 Malaria Artemether 20mg-Lumefanthrine 120 mg Tablet 
(LA 4x6 tab) 
7 Malaria Sulphadoxime500mg/Pyrimethamine 25mg 
Tablet (SP) 
8 Family Planning Depo Provera or Triclofem injection 
(Medroxyprogesterone Acetate 150 mg/mL (1 
mL) Vial) 
9 Family Planning Implanon (Etonogestrel 68 mg/Rod, 1 Rod 
Implant) 
10 Other Essential Medicines Dispersible Amoxicillin tablet 250mg 
11 Other Essential Medicines Oxytocin Injection (10units/ml) 
12 Other Essential Medicines Oral Rehydration Salt, Sachet (WHO formula) 




The primary point of data collection for the quantitative study was the study sites’ 
pharmacy store.  Prior to commencement of the study, I obtained an introductory letter from the 
MOH introducing me and the research to the study sites. The letter was presented to study site 
officials on the day of data collection.  I recruited and trained six data clerks to collect data from 
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the study sites. I also hired a supervisor to coordinate travel logistics and supervise the data 
clerks and data collation.  
I pretested the quantitative data collection tool in a health facility near Lilongwe, 
Malawi’s capital city. No problem was identified with the tool during the pretest, so the original 
version was used for data collection as designed.  
The quantitative data were collected from study sites between May 2-10, 2019. Data were 
collected with a hard copy data collection tool and uploaded into “ODK Collect,” a free and open 
source software for field data collection. 
Qualitative study: 
I purposefully selected 18 stakeholders in Malawi’s public health system to serve as key 
informants for the qualitative study based on my working knowledge of Malawi’s 
pharmaceutical and supply chain sector and key players. The key informants consisted of 
program managers, pharmacists, health facility staff, and supply chain professionals with 
medicines procurement roles in the Ministry of Health, international organizations, and donors in 
Malawi. Most of my key informants were mid- to senior-level professionals with decision 
making authority, especially in relation to essential medicines and supply chain management.  
My informants also included two heads of organizations as respondents. I contacted them either 
in-person, by phone or email to confirm date and time of the interview. I shared a brief 
description of the study with respondents using a standardized script in English. Further, I 
emphasized the importance of their contribution and how it will contribute to efforts to increase 
the availability of essential medicines in Malawi. 
I conducted 18 in-person interviews with each of the selected key informants in their 
respective offices or a private space. I obtained written consent from the participants at the time 
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of the interview.  I reviewed the consent form with them orally, and invited questions about the 
study. I described all study procedures in detail such that participants were fully informed of 
their requirements while in the study. During this consent process, I reminded participants that 
they are free to choose to take part in the research study or not. During the consent process, all 
participants were informed that information they provided through interviews will be 
confidential (i.e., not shared with anyone outside of the research team) and voluntary (i.e., they 
are not obligated to answer any question). Interviewees were told that they are free to take breaks 
and/or terminate the interview at any time. I recorded all interviews on a voice recorder and took 
written notes simultaneously with participants’ permission. All 18 participants consented and 
participated in the study. All interviews were conducted in English. 
Institutional Review Board considerations and confidentiality issues 
Institutional Review Board: I applied for IRB approval from both the University of North 
Carolina at Chapel Hill (UNC) and Malawi’s National Health Sciences Research Committee 
(NHSRC). Following the UNC IRB approval, I applied for Malawi NHSRC approval by 
submitting a hard copy application and supporting documents, including the UNC IRB approval. 
The Malawi NHSRC requires all students studying in a foreign university to submit the approval 
letter from the foreign ethics committee. I received approval from the UNC IRB via the 
electronic portal on February 2, 2019 and NHSRC’s approval on April 10, 2019.    
Confidentiality issues: I took measures to ensure confidentiality of the study sites and key 
informants. To maintain confidentiality, key informants were given a numeric identifier so their 
specific comments could not be linked to the data collected. I secured hard copies of data and 
collateral materials such as consent forms in a locked cabinet in my office. I also uploaded the 
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digitally recorded files and saved them on my password-protected computer with real time back-
up plan on Apple iCloud, a cloud storage and cloud computing service from Apple Inc. 
After the data were analyzed and the study completed, I destroyed all recordings and 
ensured that responses could not be linked to specific individuals. The results were presented in 
the aggregate and the names of the individuals were kept confidential. Descriptors of key 
informants were included as needed (e.g., their role in the health system), but participants' names 
and formal positions were not included in order to maintain confidentiality of the respondent. 
Data management 
Quantitative study: 
I collected quantitative data with a predesigned data collection tool (Appendix B) on the 
day of the visit to the facility through trained data collectors. The paper-based data were captured 
electronically and uploaded in ODK Collect. The data were exported from ODK Collect into 
Microsoft Excel files at the end of the survey. The electronic data were password protected, 
backed up on Apple iCloud, a computing service from Apple Inc. A back-up version was also 
saved in my personal password- protected flash drive. The paper-based data collection forms 
were secured in my office in locked cabinets.  
Qualitative study: 
I obtained qualitative data using a semi-structured interview guide (see Appendix C).  
Key Informants’ responses were recorded on a digital audio recorder after obtaining their 
informed consent.  I took handwritten notes simultaneously with the audio recording and 
shredded them after interviews were fully transcribed and saved as Microsoft Word documents. 
The qualitative study required collection and storage of confidential data in several formats (e.g., 
Microsoft Word documents, audio files, transcribed documents, and data analysis software files). 
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Considering the sensitivity of these data files, I saved the files in a personal laptop that is 
password protected.  
Data analysis  
I analyzed the quantitative and qualitative data separately at different times based on the 
explanatory sequential mixed methods approach (Creswell 2014), beginning with the 
quantitative data followed by the qualitative data.   
Quantitative phase:  
At the completion of quantitative data entry in ODK Collect, the data collection 
supervisor validated all data from the survey sites and exported them to Microsoft Excel for 
analysis. I checked and validated the data in Microsoft Excel to correct missing or erroneous 
entries. 
I analyzed the quantitative data in Microsoft Excel with support from my data collection 
supervisor who is experienced in quantitative data analysis. The quantitative review entailed a 
descriptive analysis of the dependent and independent variables in Table 4.  I classified the 
variables of interest according to the type (i.e., continuous or categorical) and categorized (i.e. 
interval, nominal, or ordinal).   
Table 4: Independent and Dependent Variables 
Variable Variable Type 
Independent variable  
Individual medicines Categorical (Nominal) 
Category of medicines (HIV/AIDS, Malaria, Family planning, 
and other essential medicines) 
Categorical (Nominal) 
Health facility type (primary, secondary, or tertiary care) Categorical (Ordinal) 
Location (district, regional, national) Categorical (Ordinal) 
Dependent variable  
Percent of health centers that have tracer medicines available in 
their inventory on the day of data collection 
Continuous 




The aim of the quantitative analysis was to use descriptive analysis to show the 
availability of essential medicines at different health facilities at district, region and national 
levels.  The analysis also compared the level of availability across the different types of essential 
medicines.  Data analysis for individual and categories of medicines included per cent 
availability and average per cent availability and ranges (i.e., minimum/maximum). I 
summarized and organized the data as tables and graphs (e.g., bar charts). I also compared results 
on the availability of medicines across districts, regions and categories of medicines.  For 
example, I determined how availability of HIV/AID medicines compared with availability of 
malaria medicines at regional or national levels, and according to level of care – primary, 
secondary or tertiary healthcare facility. I also determined the proportion of health facilities that 
had all the essential medicines on the day of visit and compared availability between government 
managed public health facilities and those belonging to faith-based institutions.  
Both GoM and CHAM managed public health facilities receive donated HIV/AIDS, 
malaria, family planning medicines either from the government medical stores or directly from 
donors and dispense them at no cost to the patients. Meanwhile, GoM managed district hospitals 
and health centers, excluding central hospitals, can only receive the other essential medicines – 
Dispersible Amoxicillin, Oxytocin and ORS from one supply source, the government medical 
stores, and dispense them free to patients. The CHAM managed public facilities can either 
procure their essential medicines from the government medical stores or from private 







  The second phase of data analysis focused on review of the qualitative data from KIIs. I 
digitally recorded the key informant’s information and transcribed them manually in English. 
The recorded files were stored on my personal laptop computer and secured with a password, 
and each file was coded to protect the identity of my respondents. I also took notes during the 
interview to enable me to highlight key points and for back-up purposes. I proofread and verified 
the transcribed data to eliminate errors and validate results.  
 I adopted Creswell’s (2014) approach for qualitative data analysis, which suggests a 
linear, hierarchical approach to data analysis, building from bottom to top (Figure 4).  
 




I read the transcripts in full and wrote memos to capture key ideas and themes followed 
by a content analysis, I identified themes and categories prior to coding the data. I created a 
qualitative codebook in Microsoft Excel for data analysis. The themes were tailored to my 
research questions, specifically those focused on factors that contribute to availability (enablers) 
or shortage (barriers) of the essential medicines surveyed and key informants’ suggestions to 
increase availability of the essential medicines.  
The coding was based on predetermined factors from my conceptual model or from 
emerging factors identified by key informants. I created a separate file and compiled notable 
quotes from my key informants. I incorporated the quotes in my analysis to elucidate findings 
from the qualitative study and highlight new ideas.  
 I compiled a table of the codes and systematically analyzed responses from my key 
informants. I reviewed the results to establish common themes, relationships, and areas of 
divergence. To increase the reliability of my study, I requested a DrPH graduate from UNC to 
conduct a “reality check” on my coding. All discrepancies between my codes and the second 
reviewer’s codes were investigated to ensure consensus and improve the quality of the coding 
exercise. 
I aggregated the data into nine major themes and presented them in my Chapter five. The 
key themes enabled me to understand the various factors that contribute to the availability or lack 
of essential medicines in Malawi’s public health sector. 
The final phase of my data analysis was focused on interpretation of results from the 
quantitative and qualitative studies. I used results from the qualitative study to explain results 
from the quantitative study by providing more depth and insight on availability of essential 
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medicines in Malawi’s public health facilities including factors responsible for the observed 
results and trends. 
Study limitations 
A major limitation of this study was that the quantitative data was based only on the 
availability of the medicines on the day of survey.  These data may not reflect average monthly 
or yearly availability.  Another limitation was the scope of essential medicines; the study did not 
include essential medicines for treating other disease conditions of public health significance like 
diabetics, hypertension or medicines used for other maternal and child health conditions. An 
essential medicine could become unavailable as a result of a global disruption of supply chains 
from all suppliers. That type of barrier to availability would be beyond the control of Malawi's 
MOH and health system and could arise despite their best efforts. 
  My study might be prone to selection bias, since I purposively selected the key 
informants for the qualitative phase study.  Finally, the quality and amount of information from 
the key informants is subjected to respondent bias, it might depend on their knowledge of 
Malawi’s public health and medicines supply system, and the key informant responses might not 
capture all the contextual issues that affect the availability of essential medicines in Malawi’s 











CHAPTER 4: RESULTS 
 
 Quantitative study 
A total of 131 health facilities were surveyed across Malawi’s three regions.  These 
include 29 facilities in the North region, 64 in the Central region, and 38 in the Southern region 
(Table 5).  Data were collected from all study sites producing a response rate of 100 percent.  
Table 5: Quantitative study sites 





1 Kasungu 13 
Central 64 49% 2 Lilongwe 31 
3 Ntcheu 13 
4 Salima 7 
5 Karonga 7 
North 29 22% 6 Mzimba North 12 
7 Nkhata Bay 10 
8 Blantyre 13 
South 38 29% 9 Chikwawa 9 
10 Machinga 8 
11 Mulanje 8 
Total  131 
  
  100% 
 
The survey sample included government owned public facilities and those managed by the 
Christian Health Association of Malawi (CHAM), a faith-based organization. All three levels of 
healthcare were included in the survey:  primary, secondary and tertiary facilities.   Data were 





Figure 5: Map of Malawi showing essential medicines survey sites 
Availability of essential medicines by category 
The essential medicines surveyed were grouped into four categories based on their 
indication for use. The essential medicines surveyed were either essential medicines used for 
HIV/AIDS, Malaria, Family Planning or essential medicines used for other health conditions 
(Table 6). The number of essential medicines per category range from five to two: HIV/AIDS 
medicines (two), Malaria medicines (five), Family planning (two) and other essential medicines 
(three). Malaria had the highest number of medicines in its category because the selected 
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medicines are all first line treatment for malaria and prescribed according to patients’ weight 
band. Medicines used for treatment of HIV/AIDs were the most commonly available at 99 
percent, while “other “essential medicines”, Dispersible Amoxicillin, Oxytocin injection, and 
Oral Rehydration Salt (ORS) were the least available with combined average availability of 53 
percent, figure 6. 
Table 6: Availability of essential medicines surveyed by category 
 
 





1 HIV/AIDS Dolutegravir/Lamivudine/Tenofovir Disoproxil 




2 HIV/AIDS Zidovudine/Lamivudine/Nevirapine 
60mg/30mg/50mg Tablet (Regimen 2P) 98% 
3 Malaria Artemether 20mg-Lumefanthrine 120 mg Tablet 
(LA1x6 tab) 99% 
Malaria 94% 
4 Malaria Artemether 20mg-Lumefanthrine 120 mg Tablet 
(LA 2x6 tab) 91% 
5 Malaria Artemether 20mg-Lumefanthrine 120 mg Tablet 
(LA 3x6 tab) 90% 
6 Malaria Artemether 20mg-Lumefanthrine 120 mg Tablet 
(LA 4x6 tab) 95% 
7 Malaria Sulphadoxime500mg/Pyrimethamine 25mg 
Tablet (SP) 93% 
8 Family 
Planning 
Depo-Provera or Triclofem injection 

























Oral Rehydration Salt (ORS), Sachet (WHO 





Figure 6: Availability of essential medicines by category 
Availability at all public health facilities 
 Availability of the 12 essential medicines surveyed at study sites ranged from 35 to 100 
percent (Figure 7). Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate 50 mg/300 mg/300 mg 
Tablet (Regimen 13A) was available at all study sites on the day of visit.  Meanwhile, Oral Rehydration 
Salt used for treatment of diarrhea was the least available.  Only 35 percent of study sites had this 















Figure 7: Availability of essential medicines in 131 surveyed public health facilities 
Average availability of all essential medicines at surveyed sites 
The national average availability of all essential medicines surveyed on the day of visit 
was 84 percent across the 11 districts surveyed.  The average availability of the essential 
medicines at the district level ranged from 79 percent to 89 percent. Machinga and Salima 
districts had the highest average availability (89 percent); Kasungu and Lilongwe districts 





    Table 7: Average availability of all essential medicines at survey districts and national level 































































1 HIV/AIDS Dolutegravir/Lamivudine/Tenofovir 
Disoproxil Fumarate 50 mg/300 
mg/300 mg Tablet (Regimen 13A) 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
2 HIV/AIDS Zidovudine/Lamivudine/Nevirapine 
60mg/30mg/50mg Tablet Regimen 
2P) 
100% 100% 100% 100% 100% 100% 100% 92% 100% 100% 100% 99% 
3 Malaria Artemether 20mg-Lumefanthrine 
120 mg Tablet (LA1x6 tab) 92% 89% 100% 100% 100% 100% 100% 92% 100% 100% 100% 98% 
4 Malaria Artemether 20mg-Lumefanthrine 
120 mg Tablet (LA 2x6 tab) 85% 89% 86% 77% 97% 100% 100% 92% 100% 85% 86% 90% 
5 Malaria Artemether 20mg-Lumefanthrine 
120 mg Tablet (LA 3x6 tab) 85% 78% 100% 77% 90% 100% 100% 83% 100% 92% 100% 91% 
6 Malaria Artemether 20mg-Lumefanthrine 
120 mg Tablet (LA 4x6 tab) 92% 100% 100% 69% 100% 100% 100% 92% 100% 100% 100% 96% 
7 Malaria Sulphadoxime500mg/Pyrimethamine 
25mg Tablet (SP) 100% 100% 86% 92% 94% 88% 88% 100% 100% 85% 86% 92% 
8 Family 
Planning 
Depo Provera or Triclofem injection 
(Medroxyprogesterone Acetate 150 
mg/mL (1 mL) Vial) 
83% 50% 100% 85% 70% 88% 100% 100% 100% 92% 100% 88% 
9 Family 
Planning 
Implanon (Etonogestrel 68 mg/Rod, 




Dispersible Amoxicillin tablet 




Oxytocin Injection (10units/ml) 




Oral Rehydration Salt, Sachet (WHO 
formula) for 1-liter solution 38% 67% 43% 15% 16% 50% 75% 33% 40% 23% 57% 42% 
Average availability of all medicines 82% 81% 86% 79% 79% 89% 86% 83% 86% 81% 89% 84% 
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Average availability in government and faith based public health facilities  
Clinics and hospitals in the Christian Health Association of Malawi network (CHAM) 
had slightly higher average availability of essential medicines (88 percent) compared to 
Government of Malawi managed public health facilities (81 percent), Table 8. The average 
availability of essential medicines in both categories ranged from 25 percent to 100 percent. The 
Government managed hospitals recorded the lowest availability per item, 25 percent for ORS 
compared to 90 percent at CHAM sites. The least available essential medicine at CHAM 
facilities was Dispersible amoxicillin (48 percent), but higher than the availability at Government 

















Table 8: Average availability of essential medicines by sector 
 
Availability of all essential medicines 
Only 9 (7%) of the 131 survey sites had all the 12 essential medicines on the day of the visit 
(Table 9). The availability of all essential medicines per region is very low and ranges from 3 





S/No Category Description 
Facility Type n = 131 
Government 
n = 110 
CHAM 
n = 21 
1 HIV/AIDS 
Dolutegravir/Lamivudine/Tenofovir Disoproxil 





60mg/30mg/50mg Tablet (Regimen 2P) 99% 100% 
3 Malaria 
Artemether 20mg-Lumefanthrine 120 mg Tablet 
(LA1x6 tab) 98% 95% 
4 Malaria 
Artemether 20mg-Lumefanthrine 120 mg Tablet (LA 
2x6 tab) 92% 86% 
5 Malaria 
Artemether 20mg-Lumefanthrine 120 mg Tablet (LA 
3x6 tab) 88% 100% 
6 Malaria 
Artemether 20mg-Lumefanthrine 120 mg Tablet (LA 
4x6 tab) 95% 95% 
7 Malaria Sulphadoxime500mg/Pyrimethamine 25mg Tablet (SP) 95% 86% 
8 Family Planning 
Depo Provera or Triclofem injection 
(Medroxyprogesterone Acetate 150 mg/mL (1 mL) 
Vial) 
85% 88% 
9 Family Planning 
Implanon (Etonogestrel 68 mg/Rod, 1 Rod Implant) 79% 75% 
10 Other Essential Medicines 
Dispersible Amoxicillin tablet 250mg 
35% 48% 
11 Other Essential Medicines 
Oxytocin Injection (10units/ml) 
85% 95% 
12 Other Essential Medicines 
Oral Rehydration Salt, Sachet (WHO formula) for 1-
liter solution 25% 90% 
Average availability of all medicines 81% 88% 
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Table 9: Total number of sites with all essential medicines 













National 131 9 122 7% 93% 
Central 64 6 58 9% 91% 
South 38 2 36 5% 95% 
North 29 1 28 3% 97% 
 
Sites in the central region had the highest availability of all essential medicines at 9 % 
(n=6) compared to sites in the northern region where only 3% (n=1) had all essential medicines 













I completed 18 key informant interviews between July 5, 2019 and September 30, 2019. 
Study participants consisted of mid to senior-level individuals in the Malawi health system, 
including several heads of organizations. Informants included pharmacists, health program 
managers, and supply chain professionals working to promote availability of essential medicines 
in Malawi (Table 10). The participants had decision making authority and had the potential to 
influence the availability of essential medicines in Malawi through their organizations, programs 
or health facility. In line with my second study aim, I sought participants’ views on factors that 
contribute to and impede the availability of essential medicines in Malawi’s public health 
facilities.  Interviews were semi-structured, and   all participants expressed their views freely and 
responded to all study questions. 








Impact of Essential Medicines: 
 In three core areas, all participants stated the importance of essential medicines in 
Malawi. First, given the importance of essential medicines to prevent and treat diseases, most of 
the participants believed that essential medicines are critical inputs to healthcare delivery. 
Second, by maintaining a healthy workforce, several participants agreed that essential medicines 
contribute to the country’s economic growth. Third, some respondents recognized the impact of 
S/No Category 
1 Donor supply chain personnel (n=2) 
2 Government and CHAM health supply chain managers and advisers (n=9) 
3 Government and international organization procurement managers (n=4) 
4 Health facilities staff (n=2) 
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essential medicines on the quality of health services and customer satisfaction, noting how a 
shortage of essential medicines negatively impacts patients and healthcare workers’ morale. 
According to a participant “The essential medicines are critical for keeping people 
healthy so that they can be economically productive (Respondent 7, donor supply 
personnel)”. 
Stakeholders: 
 Participants mentioned the various stakeholders who work in the essential medicines 
space in Malawi’s public health facilities as service providers, managers, advocates or 
beneficiaries (Table 11).  
Table 11: Essential medicines in Malawi: Stakeholders 
S/No Category 
1 Academia 
2 Civil society organizations 
3 Donors 
4 Faith based organizations 
5 Government of Malawi 




I identified nine themes from my interviews (Table 12). Seven of the themes were 
derived from my conceptual model, while two are emergent themes based new insights from the 
participants. The participants’ views on factors contributing to the availability (enablers) or 
shortage (barriers) of medicines are presented in the following sections according to the 
applicable themes. Further, the themes also covered participants’ suggestions on how Malawi 





Table 12: Major Themes 
  
 
     
 
  
*Emergent code: includes monitoring and policy in Concept 
model 





Most of the respondents identified the availability of data, funding, infrastructure and 
human resources for health as key factors that contribute to the availability of essential medicines 
in Malawi. They also attributed the availability of essential medicines to donations from 
international donors and international organizations (Table13). 










 Budget: Several participants attributed the availability of essential medicines in 
Malawi’s public health facilities to host government and donor funding for procurement and 













because they are heavily funded by donors. One participant mentioned that health facilities’ 
ability to manage their medicines budget directly is a critical enabler.   
“If you look at HIV, malaria and family planning, these three categories perform very 
well because they are well funded, meaning the overriding goal of the donors that support 
these programs is that there is full supply of these commodities (Respondent 1, health 
program executive).” 
“But when it comes to essential medicines, CHAM hospitals do better because they have 
control over the budget and there is a service fee attached to it, and they know how to use 
the budget wisely because it is their own money and they are responsible and accountable 
for it (Respondent 2, health program manager)”. 
Data: Most participants identified the importance of data in managing essential 
medicines and how stakeholders rely on data to make critical supply chain decisions related to 
quantification, budgeting, procurement, and allocation of essential medicines to health facilities.  
“I think there are a number of factors that are contributing to availability of medicines in 
Malawi, there is a system that first provide data on what is being used which is the 
OpenLMIS, including DHIS 2 which provides case service data, and this data is available 
for quantification and forecasting, done on annual basis in Malawi (Respondent 7, donor 
supply chain personnel)”. 
Governance: Many respondents highlighted the importance of governance structures at 
different levels (central, regional and district) to the availability of essential medicines. One 
respondent mentioned how the Drug and Therapeutic Committees (DTC) in hospitals monitor 
the procurement and rational use of essential medicines in their hospitals, and how these actions 
contribute to the availability of essential medicines. 
“The Drug and Therapeutic Committees make decisions on what to procure and how 
much to procure and where it should actually go (Respondent 15, Health Program 
Manager)”. 
Infrastructure: Several participants mentioned infrastructure as an enabling factor that 
contributes to the availability of essential medicines. Essential medicines are regulated 
commodities, and most of them require temperature-controlled climates for storage.  Facilities 
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with adequate storage infrastructure are always able to order and store essential medicines 
according to the required standard and ensure their security. 
“So, availability of storage space is also contributing to availability of essential 
medicines, because without them, basically we are looking at security, these commodities 
have to be protected, because without them you will find out that theft could be rampant 
and then they will longer be available because they have been stolen (Respondent 18, 
government supply chain manager)”. 
Procurement: Several participants attributed availability of essential medicines to 
efficient and effective procurement systems and further identified the availability of alternative 
procurement sources as an enabler. Some of the participants believed that public health facilities 
with more than one procurement source are likely to have higher availability of essential 
medicines compared to facilities with a single source. For example, CHAM managed public 
health facilities achieved a higher level of availability of essential medicines at 88 percent 
compared to 81 percent in GoM managed public health facilities, CHAM facilities have multiple 
procurement sources, they can procure essential medicines from the government medical stores 
or private suppliers, meanwhile, most GoM managed district hospital and health centers have 
only one procurement source – the national medical stores, both constitute over 99 percent ( 635 
out of about 640) of the GoM public health facilities, only the GOM central hospitals which are 
less then one percent of the entire public health facilities (five out of 640) are allowed to source 
essential medicines from private suppliers when they are not available in government medical 
stores. According to one participant, health programs with efficient and robust procurement 
systems have a higher level of availability compared to others: 
“Looking at availability of essential medicines like HIV, Malaria and family planning, 
their availability is not the same thing, for instance if you look at HIV medicines, its 
availability is almost hundred percent, what is unique about them? I think their level of 
availability is unique because there is a robust procurement system and funding 
mechanism (Respondent 5, government supply chain personnel)”. 
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Staffing: Almost all the participants recognized the importance of human resources as a 
critical enabler of the availability of essential medicines. Health facilities need competent human 
resources to quantify, procure, manage and dispense medicines to the patients.  
“So, within the supply chain system you have the human resources, the quality of human 
resources that handles the supply chain and processes that guarantees availability is also 




Respondents identified factors that contribute to the shortage of essential medicines in 
Malawi’s public health facilities (Table 14). They attributed shortage of essential medicines in 
Malawi to inadequate funding, poor data quality, and inadequate human resources for health in 
terms of numbers of staff and knowledge of supply chains. The inability of healthcare workers to 
select priority essential medicines from the general essential medicines list and ensure 
accountability of essential medicines at the health facilities were also identified as a barrier. 
Further, participants mentioned how such governance issues as political influence and lack of 
proper monitoring of health facilities contribute to the shortage of essential medicines. 
Participants also mentioned how ineffective procurement systems can result in shortages of 
essential medicines in the public sector. 














6 Inventory management 
7 Procurement 




Below are the participants’ insights on how the barriers contribute to the shortage of essential 
medicines in Malawi’s public health facilities. 
Accountability: The respondents considered theft and diversion of essential medicines 
from public health facilities as a major barrier that contributes to shortage of essential medicines. 
They also mentioned weak monitoring and oversight of the public health facilities as a 
contributing factor, a participant mentioned an instance where medicines procured by 
government of Malawi or donated to the country were stolen, diverted to neighboring countries 
through illicit trade. 
“Another major barrier to availability is accountability of the system, the security of these 
medicines, we have had cases of people walking away with medicines from the system 
and medicines that are procured for Malawi or by the government of Malawi have been 
found in neighboring countries and this became even a national issue, when we are 
discussing theft and pilferage of medicines and this has greatly affected availability 
(Respondent 4, government supply chain manager)”. 
Budget. The participants underscored the importance of funding in ensuring the 
availability of essential medicines and how inadequate funding contributes to their shortage. 
Some participants also noted that most essential medicines funded by the Government of Malawi 
are less available due to inadequate funding compared to medicines funded by donors. 
“I know that there are some commodities that solely depends on government funding, and 
if you look at the range of commodities that are solely relying on government funding are 
the ones that the country is having a shortage of in most cases, so there is limited funding, 
especially from government (Respondent 10, Procurement and Supply Chain specialist)”. 
One participant mentioned the lack of a national health insurance program in Malawi, as a barrier 
to the availability of essential medicines.  A health insurance program could potentially 
supplement government funding for essential medicines. 
“I know the funding is not enough, so there is inadequate budget. I would also tie it to the 
fact that the government offer free healthcare, there is no health insurance or contributory 




Data: Key supply chain actions including quantification, procurement and distribution 
are based on inventory data reported by health facilities.   Most participants indicated that poor 
data quality related to supply chains contributes to the shortage of essential medicines in public 
health facilities. Some participants also noted that late reporting of essential medicines data by 
health facilities may affect the availability of data for decision making, resulting in late 
procurement or resupplies to the health facilities. A participant cited a very good example of how 
poor data quality impacts decision making and can contribute to under or over procurement of 
essential medicines due to wrong quantification.  
“So usually the quantification is not well-informed in terms of quality data particularly, it 
means that the decisions that are made on quantities to be procured are not based on 
sound or quality data (Respondent 6, MOH pharmacist)”. 
Governance: Many participants reported how governance issues can contribute to the 
shortage of essential medicines.  One participant mentioned that political influence negatively 
affects procurement decisions in the public health sector by influencing the choice and quantity 
of essential medicines to be procured.  Such influence contributes to over-procurement of 
medicines beyond national needs and under-procurement of needed essential medicines.  
“When it comes to public-sector procurement there's always political influences and we 
have had cases where you go to the Central Medical stores and you find a large number 
of what I will call a less important products in the store so large a number that at the 
current rate of consumption the medicine will last the country for the next four years. It 
will also likely expire in the system, and then you have medicines that you need procured 
in very little numbers (Respondent 4, government supply chain manager).” 
 
Some participants also mentioned health workers’ failure to comply with standard 
treatment guidelines and policies might contribute to shortage of medicines.  For example, when 





“Another thing I would say is non-adherence to policies, on that one I will say may be the 
prescribers might not be prescribing according to stipulated guidelines, which lead to 
wastage and shortage eventually (Respondent 17, hospital pharmacist)”. 
Infrastructure: Some participants felt that inadequate infrastructure negatively impacts 
the availability of essential medicines in public health facilities. Several participants noted how 
inadequate medicine storage facilities at the clinics contribute to the shortage of essential 
medicines. Clinics with limited storage space are unable to store adequate supplies of essential 
medicines to meet client demand. One participant underscored the importance of information, 
communication and technology (ICT) tools in ensuring the availability of essential medicines, 
and how lack of computerized inventory management systems can limit health workers’ and 
warehouse officers’ ability to effectively manage their medicines inventory and ensure the 
availability of essential medicines at public health facilities. One participant described how poor 
road infrastructure affects the delivery of medicines from central warehouses to health facilities, 
especially in areas with poor road conditions. 
“It is simply because of our infrastructure in terms of roads for example, the HIV 
program goes out every two months to replenish medicines, however there are some very 
hard to reach areas which our warehousing and distribution agent fails to go to those sites 
at specific times of the year, so sometimes this can cause a shortage (Respondent 11, 
Ministry of Health Official).” 
Inventory management: Several participants noted how poor inventory management 
practices contribute to the shortage of essential medicines at public health facilities.  Poor 
inventory management may include lack of attention to expiry dates, which is consistent with the 
widely adopted concept of “First-to-Expire-First-Out.” Non-compliance with this practice often 
results in medicine expiration. Finally, participants mentioned how inadequate and delayed 
resupplies from central warehouses contribute to shortages at the public health facilities. 




“I think in terms of deliveries, there are quite a number of instances where health 
facilities do complain of sometimes late delivery of medicines which have an ultimate 
impact on commodity availability (Respondent 16, Pharmacist).” 
Procurement: Many participants explained how inefficient procurement systems 
contribute to the shortage of essential medicines in public health facilities.  For example, one 
participant described how poor procurement actions may result in over- or under-supply of 
essential medicines.   Participants also cited how poor choice of procurement methods can lead 
to a shortage of medicines.  For example, over-dependence on local procurement methods robs 
the organization or government of the benefit of buying medicines at cheaper and more 
competitive prices when the medicines are sourced from international and competitive bidding. 
Another participant identified the single source procurement system for government managed 
hospitals as a barrier that can contribute to the shortage of essential medicines, especially if the 
national central warehouse does not have the desired medicines in its inventory. According to 
one participant:  
“Another one is that currently the system with the government is that we have to procure 
from the central warehouse which is the Central Medical Stores, so each and every 
hospital have to buy their medicines from the central warehouse, so if the item is not 
available at Central Medical stores which is the central warehouse, which means the 
hospital will not have that item (Respondent 14, hospital pharmacist).” 
Product selection: Some participants mentioned how inefficient choice of medicines can 
contribute to shortage of essential medicines. When supply chain managers procure non-critical 
medicines, it may deplete the resources available to purchase the most critical essential 
medicines. According to one of the participants: 
“So since the drug funding  was decentralized the decision to procure which medicines 
are made by the local authorities, so sometimes they may not give priority, so some 
District Health authorities might have their own priorities, they may spend the approved 




Staffing: Several participants noted that shortage of skilled healthcare workers also 
contributes to the shortage of essential medicines in Malawi’s public health sector.  One 
participant illustrated how use of non-skilled workers can result in a shortage of essential 
medicines due to poor management of medicines.  
“When you have people that do not have the necessary skills managing your medicines 
then the drugs are subject to waste or damage when they are wrongly stored or wrongly 
issued to patients, so that is also another major barrier to availability (Respondent 4, 
government supply chain manager).” 
One participant indicated that lack of deliberate action by government to retain healthcare 
workers may also contribute to healthcare worker attrition from the public to the private health 
sector. 
“In terms of human resources, the numbers that have been trained and not enough, even 
the people that are trained, overtime they leave, creating gaps, also the capacity of the 
training institution is low to meet the needs,  so the people that are trained are leaving 
through  attrition to the private sector,  I also  see these challenges in terms of absorption 
when they graduate from the training institution,  in terms of being employed into the 
government system after completion of training (Respondent, 7 donor supply chain 
personnel).” 
How to increase availability of essential medicines 
 
All participants suggested ways that the Government of Malawi, donors and other 
stakeholders can increase the availability of essential medicines in Malawi. They identified the 
need for host government and stakeholders to increase human resources for health to effectively 
manage the medicines from sourcing through to the point at which they are dispensed to end-
users (patients). 
“We need to improve human resource for supply chain. Human resource for supply chain 
is very critical, one, for handling of medicines, for reporting, and for exercising control 
on the use of medicines (Respondent 15, program manager).” 
Study participants also recommended that the Government of Malawi should increase its 
essential medicines budget to address the shortage of essential medicines.  Some participants 
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suggested that the government should explore other approaches to generating additional funds 
for essential medicines. They recommended the introduction of consultation and medicines fees 
in Malawi's public health facilities as an additional funding source.  They also suggested the 
need for government to introduce a health insurance scheme as a sustainable way to generate 
funds for essential medicines.  According to one of the participants: 
“Government can introduce a fee, so that people can be contributing to the services they 
access from health facilities, like fee for medicines, because that will ensure that 
government is getting a top up on what they already provide to the facilities for drug 
budget (Respondent 17, hospital pharmacist).” 
Many respondents also highlighted the need to prevent theft and mismanagement of 
essential medicines through improved monitoring of healthcare workers and implementation of 
accountability measures. According to a senior government official: 
“If the government can just improve the monitoring and accountability mechanism, that 
can lead to high levels of availability of medicines in the public health facilities, because 
the Improvement in accountability will ensure that that tablet that has been bought will 
find its way to the patient for which that tablet was intended and it doesn't go to anywhere 

















CHAPTER 5: DISCUSSION 
 
This study was designed to respond to my research question “How can the availability of 
essential medicines in Malawi’s public health facilities be improved?” The aims of my research 
questions are:  
(1) What is the current status of the availability of essential medicines in Malawi’s public 
health facilities?  
(2) What are the factors that contribute to and impede the availability of essential medicines 
in Malawi’s public health facilities? 
The medicines surveyed in this study are of high public health significance in Malawi. They 
are used to manage or treat four of the six leading causes of death in Malawi, HIV/AIDS, lower 
respiratory infection, diarrheal diseases, and Malaria (IHME 2018). 
I applied a mixed methods study design to address answer my study questions. In the first 
phase, I used a quantitative study to determine the current availability of essential medicines in 
public health facilities.  In the second phase, I used a qualitative study to explore the factors that 
contribute to or impede the availability of essential medicines.   My study participants also 
suggested ways the Government of Malawi and stakeholders can increase the availability of 
essential medicines in public health facilities. I found their insights helpful in developing my 





Current status of essential medicines availability 
 
The quantitative study shows that availability of the twelve essential medicines vary 
across medicine category, districts, regions and type of health facility. It further shows that 
stockout of some essential medicines remains a problem in Malawi. 
The availability of essential medicines varied between 35 and one hundred percent. The 
most available medicine was Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate 50 
mg/300 mg/300 mg Tablet (Regimen 13A), a commonly prescribed medicine for HIV/AIDS, 
while Oral Rehydrate Salt (ORS), used for the treatment of diarrhea disease was the least 
available. Only 35% of the sites had the medicines in stock on the day of visit. 
The quantitative study shows that medicines classified as “other” essential medicines 
(Oxytocin, Dispersible Amoxicillin and ORS) were the least likely to be least available. On the 
day of study, these medicines were available in only 53% of facilities. The likely explanation for 
this is due to their funding source, the Government of Malawi annual budget. Meanwhile, the 
donor-procured essential medicines for HIV/AIDS, malaria, and family planning had availability 
averaging 99%, 94% and 82% respectively. According to the key informants, most of the 
HIV/AIDS, malaria and family planning medicines in Malawi are procured by donors with very 
little contribution from the host government, while other essential medicines are funded by the 
Government of Malawi. Essential medicines for HIV/AIDS malaria and family planning are 
mostly distributed in a donor-funded parallel supply chain that is better resourced than the 
commodities managed through the public sector supply chain. The Government of Malawi’s 
health budget is often inadequate to meet national requirements. This finding aligns with results 
from literature which shows that donations can significantly contribute to the availability of 
medicines in developing countries, such as Malawi. 
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The shortage of “other” essential medicines, especially critically important medicines 
such as dispersible amoxicillin and ORS, shows that some medicines are underfunded. 
Dispersible Amoxicillin is a commonly used medicine for the treatment of pneumonia in 
children, a lower respiratory infection relatively common in children.  Sadly, pneumonia is one 
of the top causes of under-five mortality (WHO 2019) and has a significant impact on infant 
mortality rates.  Similarly, the shortage of ORS in many health facilities is very worrisome 
because it is a lifesaver and used to manage diarrheal conditions, another leading cause of 
childhood mortality (WHO 2019). This study highlights the urgent need for the government to 
consider ways to ensure the availability of these life-saving medicines to avoid preventable 
deaths among the children and other vulnerable populations. Past research shows that Malawi 
has a long history of shortage of medicines used to treat pneumonia. The study by Lufesi et al. 
(2007) found deficient supplies of drugs for life threatening diseases in Malawi. They found that 
the supply of anti-malarial drugs was somewhat better than the supply of drugs used to treat 
pneumonia.  Unfortunately, shortage of pneumonia medicines is a chronic problem in Malawi’s 
public health system, resulting in dire consequences. 
According to another study, when essential medicines are not available at public health 
facilities, patients are forced to buy them from the private sector or forgo treatment (Medis et al. 
2007). This is like the situation in Malawi.   This is particularly alarming considering the poor 
economic status of Malawi where the national poverty rate was 51.5 percent in 2016 (World 
Bank 2019). The most vulnerable populations, including women and children, may be unable to 
purchase the essential medicines from the private sector. 
The huge discrepancy between the availability of donor procured essential medicines and 
those procured by the host government presents a significant development challenge with a huge 
 
65 
impact on the population. Donor resources are not always guaranteed, so the government of 
Malawi needs to explore strategies to increase domestic funding for essential medicines to avert 
abrupt disruptions in healthcare delivery due to the unavailability of medicines or donor funding. 
My study also shows variation in the availability of essential medicines according to the 
type of public health facility. In Malawi, health care is provided by both the public and private 
sector. Up to 60% of the health care services are provided by public facilities, 37% are provided 
by the Christian Health Association of Malawi (CHAM), and 3% by the private sector (Khuluza 
et al. 2019). Public health facilities within the Christian Health Association of Malawi (CHAM) 
network had an average medicine availability of 88%, compared to 81% in facilities managed 
directly by the Government of Malawi. Findings from the qualitative study show that public 
health facilities in the CHAM network have budgets for medicine procurement and can buy 
medicines not freely available from government central medical stores.   This means that they 
have more than one source of supplies, government stores and private suppliers. The CHAM 
facilities also charge fees for certain services and medicines procured from private suppliers. 
This reinforces findings from previous studies which indicate that facilities with multiple sources 
of procurement record higher level of essential medicine availability.  
Details of the enabling factors are discussed in the next section focused on enablers and barriers 
to availability.  
The discrepancy in availability of essential medicines in government of Malawi and 
CHAM public health facilities suggests the need for a review and evaluation of the government 
supply chain system and financing schemes. It demonstrates how different supply chain models 
can affect medicine availability in clinics and hospitals. The best practices at sites and districts 
with high availability need to be explored further to help inform policy.  
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My study also revealed different levels of availability of essential medicines at the sub-
national level across the districts in Malawi. Salima district reported the highest average 
availability at 89% compared to 79% in the districts with the lowest availability, Lilongwe and 
Kasungu districts. This implies that even within the same country, district authorities have 
different level of medicine availability which might be due to different approach in management 
of supplies in terms of product selection, inventory management, data management and 
reporting, supervision and oversight, staffing and other contextual factors that will require further 
research.  
Another interesting finding from the quantitative study was the level of availability of all 
essential medicines surveyed.  Only seven percent of survey sites had all twelve essential 
medicines available on the day of visit. The remainder of facilities had varying level of 
availability and could not boast of having these 12 commonly used essential medicines. The 
situation has dire consequence for public health and may affect Malawi’s ability to address the 
health needs of the population. 
Enablers  
 
One of the aims of this study was to determine the factors that contribute to the 
availability of essential medicines in Malawi’s public health facilities. The quantitative and 
qualitative studies provided very useful insights into understanding these enabling factors.  
The quantitative study results revealed huge differences in the level of availability of 
essential medicines at the study sites.  Donated essential medicines were more widely available 
compared to the medicines procured by the Government of Malawi. The qualitative study 
participants attributed this difference to the availability of funding. The donors ensure that 
adequate budgets are made available to procure the essential medicines of interest, in this case, 
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medicines for HIV/AIDS, malaria and family planning. This finding also resonates with my 
conceptual model (Chapter 1), which identified budgeting as a critical requirement for the 
logistics cycle. This study also reinforces results from the study by Mendis et al. (2007) in six 
low-and middle-income countries (including Malawi), which highlighted the substantial role 
international donors play in the supply of medicines to the public sector. 
The qualitative study also revealed the importance of effective governance in health 
supply chains can improve the availability of essential medicines. In Malawi, the key informants 
emphatically identified the existence of laws, policies, guidelines, monitoring and supervision 
procedures, and Civil Society Organization (advocacy) as key enablers for ensuring the 
availability of essential medicines.  Without an enabling environment, it will be difficult for 
donors to step in to contribute funds and donate life-saving medicines to public health facilities. 
The existence of laws, regulations and policies also helps to guide stakeholders on key 
considerations for procurement, handling, and use of medicines.  
The key informants also highlighted the critical role played by oversight bodies in 
ensuring the availability of essential medicines, such as Drug and Therapeutic Committees in 
public hospitals.  A Drug and Therapeutic Committee reviews the hospital’s procurement list and 
plan and supports the hospital in identifying critical essential medicines to be procured with 
limited resources. Similarly, the Government of Malawi has established the Drug Theft and 
Investigation Unit (DTIU) within the Ministry of Health to investigate all reported or suspected 
cases of drug theft and diversion from public hospitals.  This is a major challenge in Malawi’s 
public health sector. Although studies from my literature review did not identify governance as a 
major factor impacting the availability of essential medicines, my findings support the need to 
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prioritize governance issues when designing essential medicines programs for countries or 
organizations.  
The qualitative study confirmed the importance of efficient procurement systems as a 
critical enabler for ensuring availability of essential medicines. This was also demonstrated in the 
quantitative study, where most donor organizations have very efficient procurement systems that 
enable them to plan and procure essential medicines at very competitive prices in line with best 
practices. Key informants supported my conceptual model, which identified efficient 
procurement systems as a critical requirement in ensuring the availability of essential medicines. 
The quantitative results in this study show high level of availability of donor procured essential 
medicines compared to those procured by the host government. 
Availability of adequate infrastructure is also a critical factor contributing to the 
availability of essential medicines in health facilities.  Although my conceptual model considered 
availability of adequate warehouses for storing medicines in secured and optimum condition as a 
key requirement, my key informants mentioned other critical infrastructural requirements. These 
included the availability of good road infrastructure as a key determinant, because poor road 
conditions hinder access and timely delivery of essential medicines to public health facilities, 
especially those in hard to reach areas.  One key informant acknowledged the importance of a 
reliable information communication and technology (ICT) infrastructure for effective inventory 
management. Public health facilities need functional computers, inventory management 
software, and power to manage their essential medicines and medical supplies.  
This study underscores the importance of adequate and skilled human resources in 
ensuring the availability of essential medicines. My conceptual model also recognized staffing as 
a critical element in the logistics cycle. According to my participants, most of the donor 
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supported HIV/AIDS, Malaria and Family Planning programs have dedicated supply chain 
experts that work to ensure consistent availability of essential medicines for their respective 
programs. They further linked the high level of availability (between 99% and 84 %) of donor 
procured essential medicines in this study to the presence of skilled procurement and supply 
chain expertise in the HIV, Malaria and family planning programs, compared to the host 
government-managed essential medicines program with only 54% average availability. 
Barriers 
 
As part of my qualitative study, I identified factors that contribute to the shortage of 
essential medicines in Malawi’s public health facilities.  I refer to them as barriers in subsequent 
sections. Interestingly, most of the enablers identified in this study can also be barriers when they 
are not adequately provided. 
The participants identified several barriers that impede on availability of essential 
medicines at study sites. They made a very strong connection between inadequate supply chain 
human resources and shortage of essential medicines.  For instance, the participants attributed 
the shortage of medicines procured through Malawi’s essential medicines program to inadequate 
staffing. Further, staffing issues manifest in different ways, including delayed recruitment by 
government, lack of motivation and incentives, lack of a personnel retention plan resulting in 
attrition from the public to the private sector. The participants also highlighted the implications 
of using unskilled personnel for essential medicines management and dispensing at the public 
health facilities. Some participants mentioned how use of unskilled staff was associated with 
stockouts of essential medicines due to poor inventory management, wastage, expiration of 
medicines, and dispensing errors. These findings are consistent with previous studies and my 
conceptual model.  For example, in their study of essential health products in Mozambique, 
 
70 
Wagenaar et al. (2014), attributed stockout of medicines to inadequate human resources at the 
facility level. 
Although funding emerged as a critical enabler in the previous section, participants also 
identified inadequate funding as a significant bottleneck that impeded the availability of essential 
medicines at the study sites. The quantitative study found very clear evidence to buttress this 
point.  Donor-procured essential medicines for HIV/AIDS, malaria and family planning, 
recorded very high levels of availability because of adequate and consistent funding from their 
sponsors.  On the flip side, the study sites reported shortages of government procurement of 
essential medicines (Dispersible Amoxicillin and ORS) on the day of visit. This was attributed to 
inadequate funding from the host government. This finding amplifies the fact that funding plays 
a critical role in ensuring the availability of life saving medicines at public health facilities.  
The situation in Malawi is aggravated by the fact that Malawi does not have other sources 
of health financing apart from the national budget.  Some countries are able to generate 
supplemental funding for their health sector through health insurance schemes. According to the 
Mchenga et al. (2017) study on the effects of catastrophic health expenditures, Malawi has no 
social medical insurance, and almost nonexistent private medical insurance. Thus, insurance 
plays a marginal role as a source of health care financing. 
The quantitative study participants made a very strong connection between lack of 
accountability and shortage of essential medicines. Lack of accountability manifests itself in the 
form of corruption, weak monitoring systems, and theft and diversion of medicines from public 
health facilities.  When health facility staff or their accomplices steal medicines from the health 
facilities, it reduces the quantity of medicines available for patients and contribute to their 
shortage. Similarly, when procurement officers engage in corrupt practices, such as inflated 
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contract prices or bid rigging, it limits the quantity of medicines that can be procured with scarce 
resources and creates a shortage at public health facilities. 
  Consistent with literature findings, this study also revealed how inadequate infrastructure, 
such as inadequate warehouse and lack of space to securely store medicines can contribute to 
medicine shortages.  Inadequate storage space limits health facilities’ capacity to store their 
medicines in an orderly manner which may result in poor inventory management due to 
congestion in storage areas. 
Moreover, participants also shared new perspectives on the impact of poor infrastructure 
on medicine availability.  One participant cited an example of how poor road conditions affect 
the ability of delivery vans to reach public health facilities in the affected regions especially 
those located in hard to reach areas.  Similarly, the lack of effective ICT tools impacts health 
workers’ ability to keep accurate inventory and transmit supply chain data for decision making. 
My conceptual model did not include impact of ICT on availability of essential medicines. 
Technology and innovation are emerging as key drivers for development and efficiency. It will 
be difficult to keep up with increased demand for accountability of essential medicines when 
health facilities lack basic ICT tools and infrastructure to effectively manage their supplies. 
This study also revealed how poor data quality can result in shortage of essential 
medicines in a public health system. Supply chain managers need high quality data to inform 
medicine quantification, procurement, and distribution. The participants identified several data 
issues including delayed submission of monthly reports by health facilities, and incomplete and 
poor-quality data.  Wrong or incomplete data may result in incorrect quantification and may 
result in under- procurement and over-procurements of essential medicines. Both will result in 
shortage of essential medicines and waste of scarce resources. 
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The study also generated new evidence on how governance issues contribute to shortage 
of essential medicines.  One participant emphatically mentioned how corruption and political 
influence negatively affect procurement decisions by limiting open and transparent competition 
among suppliers. In some instances, procurement decisions favor particular suppliers, and work 
against rational and evidence-based procurement decisions.  Medicines are sometimes selected 
for procurement based not on client need but on personal incentives. Such negative influences 
contribute to under- or over-supply of essential medicines. Such imbalances can distort supply 
chain planning and contribute to shortages. The participants also attributed shortage of essential 
medicines to healthcare workers’ non-compliance with policies, regulations, and standard 
treatment protocols. This can result in poor management, irrational use of medicines, and 
stockouts of essential medicines. 
The quantitative and qualitative studies demonstrated how inefficient procurement 
systems can contribute to the shortage of essential medicines. Participants highlighted how 
health facilities with only a single source of supplies - notably government public health facilities 
- are prone to more shortages compared to health facilities with multiple sources of procurement, 
such as CHAM managed public health facilities. Health facilities with multiple sources of 
procurement can easily consider alternative sources when the essential medicines are not 
available from one supplier. This result is consistent with findings from past studies, Masters et 
al. (2014), in a quantitative study on pharmaceutical availability across level of care in Ghana, 
Kenya, and Uganda revealed that in Uganda, facilities receiving pharmaceuticals from both the 










CHAPTER 6: PLAN FOR CHANGE 
 
This chapter is comprised of three sections: recommendations, plan for change and 
conclusion. My recommendations are based on the study, literature findings, and my conceptual 
model (Chapter 1).  The Government of Malawi and stakeholders can adapt them along with 
existing efforts to ensure consistent availability of essential medicines in Malawi’s public 
facilities. In the plan for change section, I developed a roadmap for addressing my research 
question, “How can availability of essential medicines in Malawi’s public health facility be 
improved”? I suggested ways the Government of Malawi and other players can join forces to 
address contextual issues affecting the availability of essential medicines in Malawi. The third 
section is the conclusion and summarizes my thoughts on availability of essential medicines in 
Malawi’s public health facilities based on my study findings. 
General Recommendations Based on Study and Literature Findings: 
 
Recommendation 1: Prioritize funding for essential medicines 
 
The Government of Malawi and partners should provide an adequate budget for 
procurement, storage and distribution of essential medicines. Without an adequate budget, it is 
difficult to meet the country’s essential medicines requirements and ensure that they are 
consistently available to patients. The government should also explore ways to increase domestic 
resources for health financing and medicines procurement. Moreover, a detailed review of the 
current medicines financing scheme will very helpful in identifying lasting and sustainable 
options to adequately fund procurement and supply management of essential medicines. This 
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study and literature recognized the critical role donations play in ensuring availability of 
essential medicines. However, donor resources, including essential medicines, are subject to 
changes in the political and economic climate at the donors’ home country or organization.  
Resources might be redirected or unavailable due to strategic shifts in priorities.  Such 
developments can pose significant challenges to recipient countries, especially if they are unable 
to identify alternative resources to fill gaps created by dwindling donor resources. 
  The study participants offered helpful recommendations on how the government of 
Malawi can generate additional domestic funds for essential medicines procurement.  Several 
participants recommended the introduction of patient fees in public health facilities for medicines 
and other services.  They attributed the shortage of some essential medicines to the Government 
of Malawi’s free health care program, and its inability to fully fund the procurement of essential 
medicines. The participants recommended the introduction of health insurance as an alternative 
funding source for essential medicines. 
Recommendation 2: Increase human resources and capacity for health supply chain 
 
Human Resources for Health (HRH) play a vital role in supply chain and essential 
medicines programs. Without adequate HRH, it is difficult to manage the complex transactions 
and systems required to ensure timely quantification, procurement, and delivery of essential 
medicines to public health facilities. Many participants recognized the need for government to 
recruit, train and retain adequate HRH for supply chain as a means of improving the availability 
of essential medicines at public health facilities. This study revealed how use of unskilled HRH 
can result in poor inventory and data management, non-compliance with standard treatment 
guidelines and policies, and dispensing errors.  These factors threaten the availability of 
medicines and contribute to shortages when they occur. 
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Recommendation 3: Ensure accountability of medicines at all levels 
 
Medicines are regulated items and, in some instances, very expensive commodities. The 
government should take concrete steps to ensure that essential medicines are properly managed 
and accounted for at all levels of the supply chain through policy, effective monitoring, and 
oversight functions. Several participants in this study identified lack of accountability, theft, 
leakage, and mismanagement of essential medicines as factors that exacerbate medicine 
shortages.   When medicines are diverted from the public system for unintended purposes 
through theft and mismanagement, it poses a significant threat to the health sector and limits 
healthcare workers’ ability to effectively meet clients’ needs. Moreover, it might affect donor’s 
confidence and force them to divert their resources to other sectors where they can demonstrate 
results and impact. 
Recommendation 4: Strengthen governance structure for essential medicines 
 
The Government of Malawi should strengthen the governance structure for essential 
medicines to sustain the positive gains and improve on current performance. The study attributed 
the availability of donor-procured essential medicines to the enabling environment and strong 
coordination platforms in Malawi.  This has attracted several committed donors to step in and 
donate life-saving medicines for public health programs. Without a viable enabling environment 
and strong coordination platform, it will be difficult to retain donors who have consistently 
delivered lifesaving essential medicines to Malawi over the years. My conceptual model 
recognized the importance of policies as an important element in the logistics cycle, but this 
study has shown the need to consider governance issues holistically beyond policy when taking 
measures to improve the availability of essential medicines in the public sector. For instance, 
GoM should explore ways to: leverage private sector service providers in its public health supply 
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chain ecosystem; enhance coordination among the stakeholders (page 63); strengthen the 
medicines regulatory authority; embark on supply chain reforms as needed and adapt to changes 
in public health program priorities; demonstrate leadership and commitment to address policy 
and other barriers that limit the availability of essential medicines. 
The participants also emphasized the need for the government of Malawi to strengthen 
policies, coordination, and benchmark performance, and to integrate parallel supply chains as 
levers for ensuring availability of essential medicines in Malawi’s public sector. They also 
suggested that the government should ensure that stakeholders comply with all policies and 
guidelines that promote the availability of essential medicines in public health facilities, for 
instance, a participant emphasized the need for clinicians to  ensure rational use of medicines and 
only prescribe medicines for confirmed disease conditions. Irrational use of medicines 
contributes to medicine shortages and may result in unintended impacts on patients. 
Recommendation 5: Strengthen Data systems 
 
Like other aspects of global health, supply chain management is a data driven function. 
This study demonstrated the impact of data on supply chain functions, including quantification, 
procurement, and inventory management. Inaccurate data may result in poor decision-making by 
program managers and contribute to the shortage of essential medicines through misprocurement 
and expiration of medicines in warehouses or health facilities.  
The government of Malawi should invest in supply chain data systems to increase the 
quality and availability of data for decision making. Program managers and healthcare workers 
need accurate data to plan, quantify, and procure their essential medicines requirements. A 
participant raised a very important point, which emphasized that government should go the extra 
mile in promoting a culture of data use among supply chain managers and health workers. 
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Increased data use among stakeholders bolsters efforts to develop synergies among players, 
improve coordination efforts - especially those focused on ways to increase the availability of 
essential medicines -and avert duplication of efforts. 
Recommendation 6: Improve essential medicines procurement system 
 
Governments and organizations should establish efficient procurement systems for their essential 
medicines program. This study demonstrated the strong link between efficient procurement 
systems and availability of essential medicines. For instance, the HIV/AIDS, Malaria, and 
Family Planning medicines were widely available at the study sites since the medicines are 
procured from the donors’ efficient procurement systems. Meanwhile, some participants 
attributed the shortage of government procured essential medicines to weak contract 
management procedures and inefficient procurement systems in the national government system. 
This study and past literature suggest that public health facilities with multiple sources of 
procurement have higher levels of medicine availability compared to those restricted to only one 
source of procurement. 
The participants offered helpful suggestions on how to increase the availability of 
essential medicines through changes in procurement policies.  Specifically, they recommended a 
policy change that will allow public health facilities to procure essential medicines from private 
suppliers when they are not available from government central medical stores. The host 
government and organizations should also consider both local and international bidding methods 
for procurement as an option to secure the most competitive prices.   When the government and 
partners procure essential medicines at competitive prices, they are able to buy more medicines 
and reduce potential shortages associated with expensive procurements. Further, when the 
government and organizations procure essential medicines at exorbitant prices, it reduces the 
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quantity of the medicines they could have procured with the same budget at more competitive 
prices. Government and procurement agents should also consider ways to establish strong and 
robust contract management systems and hold suppliers accountable. Weak contract 
management procedures can result in delay in supplies, and even delivery of substandard 
medicines, result in shortages of essential medicines or monetary loss. 
Limitations: 
 
The recommendations above are based on the views of the study participants, my 
conceptual model, and literature review. Participants’ views are based on their working 
knowledge and experience as supply chain practitioners or healthcare workers in Malawi. Other 
limitations resulting from the quantitative and qualitative studies were discussed in Chapter 4. 
Plan for Change 
 
As a public health supply chain professional and leader, I have spent the last two decades 
working with governments and organizations in Sub-Saharan Africa to improve the availability 
of essential medicines in countries and programs. This section describes how I will apply John 
Kotter’s Eight Step Model for Leading Change (Figure 9) to support the implementation of my 
recommendations.   I will consider current efforts in Malawi to improve the availability of 
essential medicines in public health facilities as I implement the steps below with the Malawi 








Figure 9: John Kotter’s Eight Step Model for Leading Change: Adapted from Kotter 1996 
Step 1: Increase Urgency 
 
I will share the results widely with the Ministry of Health (MOH) team and other 
stakeholders who are working to increase the availability of essential medicines in Malawi. I will 
emphasize the critical gaps in availability of life-saving medicines identified in this study.  
Specific attention should be given to shortages of dispersible amoxicillin and ORS because both 
medicines are first-line treatments for pneumonia and diarrhea in children, two of the top five 
causes of death in children under-5 years (WHO 2019). 
I will emphasize the urgency involved and why stakeholders need to act swiftly to 
provide these medicines and avoid preventable deaths among this vulnerable population.  
Addressing this gap in medicine availability will enable Malawi to lower its health infant 





Step 2: Build Guiding Team 
 
Efforts to increase availability of essential medicines in Malawi public health facilities 
will entail a change process. I will work with the MOH to identify a team and champions that 
will implement this study’s recommendations. The aim is to increase their awareness and 
identify opportunities for change. To drive this agenda, I will also engage the support of 
leadership in various organizations that are working on essential medicines programs.  
I will explore opportunities to present my findings at relevant technical working groups, 
including the Drug and Medical Supplies Technical Working Group (DMS-TWG). Supporting 
this effort is my position as co-chair of the DMS-TWG in Malawi, a coordination platform for 
the MOH and donor organizations on medicines and supply chain programs in Malawi. I will 
leverage my position to share findings with DMS-TWG members and enlist them as advocates 
for improved availability of all essential medicines in Malawi’s public health facilities. 
Step 3: Develop a Vision 
 
This study demonstrated the importance of essential medicines to the health of 
Malawians and the economy. I will work in a consultative manner with MOH leadership to 
develop a vision on what the Government of Malawi seeks to achieve in the short- and long-term 
regarding availability of essential medicines. I will encourage the MOH to consult widely with 
relevant stakeholders to assess the situation and develop a vision that is realistic in scope and 
time. 
Step 4: Communicate for Buy-in 
 
To achieve the vision developed in step 3, the MOH needs buy-in from relevant 
stakeholders. To achieve buy-in, I will encourage the MOH to disseminate the vision widely in 
English and local languages to all key stakeholders, including supply chain and program 
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managers, donors, civil society organizations, the press, politicians, District Health Officers, 
head of hospitals and clinics, healthcare workers, and patients. To increase chances of success, I 
will encourage the MOH to develop tailored messages for the various stakeholders according to 
literacy level, interest, roles and knowledge. Furthermore, I will encourage the MOH to 
disseminate the vision through billboards, print and electronic media, and at meetings, 
conferences, workshops, and staff orientation programs. 
Step 5: Empower Action 
 
Some participants identified strong partnerships and coordination among stakeholders as 
an important pathway for ensuring availability of essential medicines in public health facilities. I 
will encourage the MOH to provide leadership and create an enabling environment for actions 
that will bolster the availability of essential medicines in public health facilities. I will support 
MOH leadership to create evidence-based policies, guidelines and job aids to promote the 
availability of essential medicines at public health facilities. Policies will include strategies to 
address the factors contributing to the shortage of essential medicines. 
I will encourage the MOH to empower program managers and healthcare workers to take 
actions through supply chain review meetings, supportive supervisions, and mentorship 
programs. 
Step 6: Create Short Term Wins 
 
To demonstrate progress and maintain momentum, I will support MOH efforts to monitor 
and evaluate progress on efforts to increase availability of essential medicines in public health 
facilities. The MOH will report on the achievement of key milestones and communicate short-
term wins that contribute to the overarching vision of improving the availability of essential 
medicines. For instance, the MOH can demonstrate the impact of improved availability of 
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essential medicines three or six months after implementation of improvement strategies agreed 
upon by the MOH and stakeholders.  Such reviews and updates can motivate stakeholders to stay 
on course and deliver more results. 
Step 7: Don’t Let Up 
 
Like other public health efforts, implementation of programs to improve the availability 
of is a complex and very difficult task considering the processes and resources required. I will 
encourage the MOH and stakeholders to stay focused on its vision (step 3), and continually scan 
the environment for threats and risks that may impede the availability of essential medicines in 
the public health facilities. I will support the MOH in finding ways to encourage stakeholders to 
document and report challenges, and to maintain collaborative efforts to achieve the vision.   
Step 8: Make Change Stick 
 
This study demonstrated how lack of human and material resources, including 
governance issues, impede the availability of life saving medicines in the country. I will support 
MOH efforts to continually monitor and assess progress with the aim of sustaining the positive 
gains. I will encourage MOH leadership to institutionalize best practices and continue to review 
them to ensure they are relevant.    
I will also support the MOH to incorporate supply chain best practices in healthcare 
workers’ training curriculum, case studies, Standard Operating Procedures (SOPs), and job aids. 
This approach will potentially reinforce positive behaviors and promote a culture of continuous 
learning among practitioners. 
Limitations 
 
This plan for change is subject to significant limitations. First, I am neither a staff of the 
Ministry of Health nor the Government of Malawi.  My recommendations are subject to the 
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MOH’s leadership decision to consider or shelve them. Given their potential impact on health 
outcomes, I intend to build on my excellent working relationships with the Malawi MOH and 
donors, and encourage them to consider my recommendations. Second, the recommendations are 
not exhaustive, but are based on my study findings, past literature and working knowledge of the 
Malawi public health sector between 2012 and 2020. Third, successful engagement of other 
stakeholders to implement and monitor the recommendations will depend on the readiness of the 
MOH to convene the meetings, and provide the resources to create the enabling environment for 
implementation. 
Additional Plans for Disseminating Findings beyond Malawi 
 
I strongly believe that my results and recommendations are relevant to global health and 
developing countries, especially Sub-Saharan African Countries. I intend to disseminate my 
findings widely beyond Malawi through abstracts and publications in peer review journals. I will 
consider opportunities to also share my findings at International public health supply chain 
conferences or meetings. 
Further, I intend to apply the findings and lessons from this study to my routine work as 
an international supply chain expert and public health practitioner. I will find them very useful as 
I design, implement, and monitor supply chain projects that are working to improve availability 
of essential medicines in my country of assignment. 
Conclusion 
 
Despite the Government of Malawi and donors’ effort to improve the health supply chain 
system, significant shortages of some life-saving essential medicines remain a challenge. Donor 
procured medicines for HIV/AIDS, malaria and family planning are widely available at public 
health facilities compared to Government of Malawi procured medicines for maternal and child 
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health, including Oxytocin, Dispersible Amoxicillin and ORS. Without adequate availability of 
all critical and life-saving essential medicines, it will be difficult to improve health outcomes and 
avert preventable deaths among vulnerable population, especially women and children. 
To ensure consistent availability of essential medicines in the public sector, the 
Government of Malawi should take concrete steps to address the inadequacies in funding, human 
resources, and infrastructure, as well as the lack of accountability. The Government of Malawi 
should also address several issues that impact the availability of essential medicines, such as 
poor-quality data, inefficient procurement systems, and governance challenges. 
Without adequate supplies of essential medicines at public health facilities, it will be 
difficult for Malawi to meet the United Nations Sustainable Development Goal number three to 
ensure healthy lives and promote well-being for all at all ages (UN 2015).  At the national level, 
it will hinder the Ministry of Health’s ability to meet its Health Sector Strategic Plan II Objective 
5: Improve the availability, quality and utilization of medicines and medical supplies (MOH 
2017). 
This study builds on past studies to make a compelling case for an urgent intervention by 
Government of Malawi and donors with regards to the availability of essential medicines. 
Although the recommendations represent the views of the researcher, study participants, and past 
studies, it presents an excellent basis for initiating discussion on options to sustainably increase 




APPENDIX A: SUMMARY OF LITERATURE REVIEW FINDINGS 
  




Results: Availability of essential 
medicines, barrier and enablers Study Design Population Study Limitations 
Access to 
essential 












2016 Medicines used 
to treat chronic 
respiratory 
disease in public 
and private 
sector 
Availability: Shortage of essential 
medicines for CRD. Beclomethasone is 
only available in 38% of public facilities 
in Malawi 
 
Barriers: Lack of acceptance of essential 
medicines by some specialists and the 
standardized management of asthma 
 
Enablers: Use of Asthma Drug Facility 
(ADF), health work training, political 
commitment, free care, standardized 




Public and private 
health facilities in 
LMIC: Malawi, 
Burkina Faso and 
Guinea. 
Not original research, 
reviewed findings from 
other studies. Prone to 




of preterm birth: 
A multi-country 










Liu et al.  2015 Antenatal 
corticosteroids 




Availability: nine out of eleven countries 
identified essential medical products and 
medical technology as a bottleneck 
 
Barriers: Lack of inclusion of ACS on the 
national essential medicines list (NEML) 
for fetal lung maturation: Non-inclusion of 
ACS in national quantification and 
forecasting 
 
Enablers: Include ACS in national 
essential medicines list; Develop and 
disseminate policy in health facilities to 
enhance procurement; Estimate needs 
based on number/estimate of preterm birth 
load at health facilities 










Country level survey 
among program 
managers. Consensus 
views are subjective. 
Information. The quality 
and amount of 
information varied 
depending on knowledge 
of participants on health 









Results: Availability of essential 
medicines, barrier and enablers Study Design Population Study Limitations 
Deficient supplies 
of drugs for life 
threatening 














2007 Medicines used 




malaria in public 
health facilities 
Availability: Shortage of life saving 
medicines, cumulative stock out days of 5 
months and 4 months respectively of 
pneumonia and malaria medicines 
respectively 
 
Barriers: Insufficient deliveries from the 
Regional Medical Store. 
Stocked supplies not recorded as having 
been given to patients, Uneven distribution 
of drugs among health centers, lack of 
training 
 





Eight public health 
centers in Lilongwe 
district 
Small sample size (n=8) 
questions external 
validity. Surveyed only 






improve after the 
conversion of 
central medical 




























Availability: Overall results showed an 
improvement of drug availability at both 
the CMST and KCH after the change from 
CMS to a Trust. In contrast, for QECH 
there was no improvement for the time 
period 
 
Barriers: Central Medical Stores (CMS) 
as a government department 
 








Two central tertiary 
hospitals and one 
central medical 
store  
Small sample size (n=2) 
questions external 
validity. Surveyed only 
tertiary hospitals. 
Excluded district 
hospitals and health 
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Availability: product availability is weak 
in each country, with more than half of 
CHWs stocked out of at least one tracer 
product on the day of the assessment 
 
Barriers: product availability at CHW 
resupply points; supply chain knowledge 
and capacity among CHWs and their 
supervisors, and availability of appropriate 
transportation 
 




705 CHWs, 42 
central, district, 
zonal and regional 
medical stores and 
275 health centers 
and district hospitals 
in Ethiopia, Malawi 
and Rwanda  
Spot survey presents a 
challenge in terms of 
validity of findings. Day 
of visit results may 
present a more optimistic 
picture than actually 
exists because they do 
not show if products have 
been in stock 
continuously, nor 
whether supply levels are 








Results: Availability of essential 
medicines, barrier and enablers Study Design Population Study Limitations 




and barriers to 
accessing under-
five child health 
services in urban 














five child health 
services 
Availability: lack of medicines and 
supplies 
 
Barriers: Not reported 
 
Enablers: Not reported 
Qualitative 100 participants 
including service 
providers and users 
in Urban slums in 
Malawi 
Lack of generalizability 
for study findings, study 



















2007 Availability of 
essential 
medicines used 
to treat chronic 
disease in public 
and private 
sector  
Availability: In all countries, less than 
7.5% of these 32 medicines were available 
in public sector, except in Brazil, where 
30% were available, and Sri Lanka, where 
28% were available. The total availability 
of medicines in the public sector was 
considerably lower in all countries. 
 










151 public facilities 
in six LMICs- 
Bangladesh, Brazil, 
Malawi, Nepal, 




method raise concerns 
with generalizability and 
reliability. Research 
focused on public health 
facilities within one-





















2013 Availability of 
essential asthma 
medicines 
Availability: The availability in public 
hospitals of generic beclometasone 100 
lg/puff was 19 % and of generic 
budesonide was 16 %. Generic salbutamol 
inhalers were available in 55 % of national 
procurement centers and 56 % of public 
hospitals. Availability was particularly 









One public hospital 
and the national 
procurement center 
in 52 low- and 
middle-income 
countries 
Results are less 
generalizable; data are 
collected from two sites 
in countries surveyed. 
 
Point-in-time sampling 








Results: Availability of essential 
medicines, barrier and enablers Study Design Population Study Limitations 
Bissell, 
Karen 
national procurement centers and main 
hospitals 
 
Barriers: many Essential Medicines lists 
are not updated; Inefficient procurement 
system, High prices of medicines 
 
Enablers: Not reported 
true status of availability 
of essential medicines 
 
Cross-sectional study 
does not allow for causal 
conclusions. Potential 
confounding variables. 
Reliance on self-reported 
data. 
The impact of 
inventory 
management on 
stock outs of 


















2016 impact of 
inventory 
management on 
stock outs of 
essential drugs 
Availability: up to 30% of surveyed 
facilities stocked out of some AL product 
during Q1 2010 despite ample inventory 
being simultaneously available at the 
national warehouse 
 






 145 public health 
facilities in Zambia 
Age of data set 2009-
2010 raise validity 
concerns; it raises 
concern whether the 
assumptions and 
conclusions of this study 
are still relevant.  
What essential 
medicines for 






















Availability: The availability of key 
essential medicines for children was poor. 
The ranges of the proportions available 
were similar: 15–70% in teaching 
hospitals and 10–80% in district hospitals. 
In primary health care clinics, the 
availability of medicines was generally 
lower than in hospital facilities, though the 
range of the proportions available was 
much smaller across countries, being 18–
48%. 
 
Barriers: Not reported 
 







Twelve public and 
private health 
facilities in each 
country’s capital 
city. 
Limited sample size, 
findings might not be 
generalizable. Study only 
surveyed medicines used 
for children in 12 study 
sites in capital cities in 14 









Results: Availability of essential 
medicines, barrier and enablers Study Design Population Study Limitations 
Access to 









2013 Access to 
essential 
medicines 
Availability: Irrational health-seeking 
behavior, demand for and use of 
medicines; Irrational prescription and 
dispensing; Low quality of health services, 
Low public accountability and 
transparency; High burden of government 
bureaucracy; International donors' agenda 
 
Barriers: Not reported 
 
Enablers: Not reported 
Not applicable Not applicable Researchers bias 
Malawi Health 
Sector Strategic 








Availability: Not reported 
 
Barriers: inadequate space for storage of 
EMS; lengthy procurement processes, 
pilferage and weak supply chain 
management is weak 
 
Enablers: Not reported 






















Availability: Shortage of medicines 
 
Barriers: Unexpected demand changes; 
Overly fragmented and customized 
procurement requirements. Unreliable data 
from peripheral facilities Supply side: 
Very limited manufacturers, quality and 
raw materials problem, long timelines for 
regulatory approval 
 
Enablers: Effective stakeholder 
discussion; Effective management of 
supply chains; Ethical medicines use; Fair 
medicines price 








Results: Availability of essential 
medicines, barrier and enablers Study Design Population Study Limitations 
Pharmaceutical 
Availability 











2014 Availability of 
essential 
medicines 
Availability: All three countries faced 
similar patterns of stock-out with the low-
level community public health facilities 
facing the highest proportion of drugs 
stocked-out. 
 
Barriers: Not reported 
 
Enablers: Presence of vehicle and 
laboratory at the health facility. In Uganda, 
both facilities receiving pharmaceuticals 
from the MOH and from private suppliers 





the time of 
survey 
administration. 
659 public health 
facilities in Ghana, 
Uganda and Kenya 
Spot survey presents a 
challenge in terms of 
validity of findings. Day 
of visit results may 
present a more optimistic 
picture than actually 
exists because they do 
not show if products have 
been in stock 
continuously, nor 
whether supply levels are 
too low or too high to 

















2011 Essential Health 
Package 
Availability: 27% of the health facility 
managers considered Cotrimoxazole (to 
treat acute respiratory tract and other 
infections) to be of sufficient supply in 
their respective facility; 60% had 
insufficient stock, while in 13% of the 
facilities it was completely out of stock at 
the time of the survey. 
 
Barriers: budgetary constraints, others 
include i) cumbersome and long World 
Bank procurement procedures, ii) 
insufficient qualified staff to perform 
quantification adequately, iii) a high 
turnover in staff, iv) poor warehousing and 
lack of space leading to drugs being 
pushed to the periphery too quickly and 
not based on need, v) poor inventory 
systems, and, vi) lack of capital funds to 
procure sufficient drugs in advance to 
cater for additional need and spoilage 
(buffer stock).. 
 




136 health workers 
and 54 public health 
facilities in Malawi 
Spot survey presents a 
challenge in terms of 
validity of findings. Day 
of visit results may 
present a more optimistic 
picture than actually 
exists because they do 
not show if products have 
been in stock 
continuously, nor 
whether supply levels are 
too low or too high to 









Results: Availability of essential 


















Availability: Only 9 per cent of local 
health facilities (54 out of 585) provided 
the full EHP list of essential drugs. Clinics 
were frequently out of basic antibiotics, 
HIV test kits, and insecticide-treated nets, 
and stocks of vaccines had run 
dangerously low 
 
Barriers: The lack of free essential 
medicines in government clinics and 
hospitals is due to a combination of poor 
investment in personnel and infrastructure, 
inadequate resources, and corruption and 
mismanagement 
 





facilities in Malawi 
(n=585) 
Not a peer reviewed 
study. Results prone to 
researcher’s bias. 
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Availability: Stock-out rates for drugs 
ranged from 1.3% for oral rehydration 
solution to 20.5% for Depo-Provera and 
condoms, with mean stock-out rate of 9.1 
%. 
 
Barriers: Distance from district 
distribution warehouses was associated 
with 31% (CI: 22-42%) drug stock outs. 
The number of health facility staff was 
consistently negatively associated with the 
occurrence of stock outs. 
 
Enablers: Not applicable 
Quantitative 
assessment 
26 clinics is Sofola 
province and 13 
district depositories 
Data collection was 
conducted at one point in 
the year (July–August) 
and therefore may not be 
representative of EHP 
availability the entire 
year. 
 
Data were entirely from 
the province of Sofola 
and may not be 
generalizable to other 
disparate areas of 













Name of Health Facility: Visit Date:
Name:    Telephone: 





Disoproxil Fumarate 50 mg/300 
mg/300 mg Tablet (Regimen 13A)
2 HIV/AIDS
Zidovudine/Lamivudine/Nevirapine 
60mg/30mg/50mg Tablet       
(Regimen 2P)
3 Malaria Artemether 20mg-Lumefanthrine 120 
mg Tablet (LA1x6 tab)- LA1
4 Malaria Artemether 20mg-Lumefanthrine 120 
mg Tablet (LA 4x6 tab) LA4
5 Malaria Sulphadoxime500mg/Pyrimethamine 
25mg Tablet(SP)
6 Family Planning
Depo provera or Triclofem injection ( 
Medroxyprogesterone Acetate 150 
mg/mL (1 mL) Vial)
7 Family Planning Implanon (Etonogestrel 68 mg/Rod, 1 
Rod Implant)
8 Other Essential 
Medicines Dispersible Amoxicillin tablet 250mg
9 Other Essential 
Medicines Oxytocin Injection ( 10units/ml)
10 Other Essential 
Medicines
Oral Rehydration Salt, Satchet (WHO 
formula) for 1 litre solution
Comments
Name and Telephone number of  
Health facility staff:
Availability 








Health facility/Organization: ____________________ 
 
Key Informant: _____________________________ 
 
Introduction       
 
 The purpose of this interview is to seek your perspectives on factors contributing to 
availability of essential medicines in Malawi’s public health facility. Specifically, I would like to 
know from your view, factors that are contributing to availability or shortage of essential 
medicines in Malawi’s public health facilities.   
 
 This interview should take about 30 minutes. Again, it will be completely confidential 
and any information that you provide will be released as a summary or combined into general 
themes. Your name will not be connected to your answers in any way.  Furthermore, your 
organization/health facility will remain blinded and will not be listed by name but as ‘an 
organization that support Malawi’s essential medicines program or health facility that provide 
essential medicines to clients’. With your permission, I would like to record our interview. 
Digital audio files and transcripts will be confidentially destroyed at the end of the research 
study. 
 
§ Are there any questions that you have about the research study or the interview? 
§ May I record the interview? 
 
I would like to start by explaining some of the terms I used when I refer to essential medicines; I 
am referring to medicines that satisfy the priority health care needs of the population. They are 
selected with due regard to public health relevance, evidence on efficacy and safety, and 
comparative cost-effectiveness. This study is focused on medicines for HIV/AIDS, malaria, 
Family planning and medicines for other common health conditions like pneumonia, and 
respiratory tract infections and maternal health.  When I use the term public facility, I mean 
places that provide health care. They include hospitals, clinics, outpatient care centers, and 
specialized care centers, in urban and rural areas.  For example, public health facility in Malawi 
include, health centers, clinics, central, district, rural, hospitals including Christian Health 
Association Malawi supported hospitals. Lastly,  the term barrier refers to anything 
that prevents or obstructs passage, access to availability of essential medicines, while facilitators 
refers to  person or thing that increase availability of essential medicines in Malawi’s public 
health facility, examples include policies, institutions, organizations, or individuals. 
 
§ Do you have any questions about the definitions before we move on?     
I am going to start with some introductory questions to better understand your organization and 
your role. 
a) What role does your organization play in the implementation of Malawi’s essential 




b) Is your organization concerned about the availability of essential medicines in 
Malawi?   Y   N 
c) What is your role in your organization? 
d) How do you support your organization to increase availability of essential medicines 
in Malawi? _______________ 
 
 
Now, I would like to talk specifically about the Availability of Essential Medicines in Malawi’s 
Public Health Facilities: Enablers and Barriers. 
 
1. Do you think essential medicines are critical inputs for health care delivery? 
Probes:  
a. Do you think government of Malawi has prioritized availability of essential medicines in 
Malawi? 
b. Give examples of actions taken by Government to ensure availability of essential 
medicines in Malawi’s public health facilities. 
 
2. If yes to question #1: If yes, can you describe how essential medicines impacts on health care 
delivery in Malawi?  If No, skip question # 2 
 
Barriers and Facilitators 
 
3. What are the factors contributing to availability of the following medicines? HIV, Malaria, 
Family planning, and essential medicines (mention list of medicines surveyed in quantitative 
study), the factors are also referred to as “facilitators”. 
Probes:  
a. How have these factors contributed to availability of the medicines listed in Malawi’s 
public health facilities? 
b. Mention specific actors or organizations that are contributing to these factors. 
 
 
4. What are the factors contributing to shortage (barriers) of the medicines listed in questions three 
(repeat if necessary)?  
a. Probes:  
b. How have these factors contributed to the shortage of these essential medicines in 
Malawi’s public health facilities? 
c. From your view, what steps has Government of Malawi (GoM) taken to address these 
barriers? Please give examples. 
d. Apart from GoM, are other stakeholders taking steps to address these barriers? Please 
mention them and give examples of steps taken to address them. 
 
Strategies for change 
 
5. How can availability of essential medicines be improved in Malawi's public health facilities? 
a. Probes:  
b. Please give specific examples of how GoM and other stakeholders (donors, CSOs, 
community) can ensure availability of essential medicines in public health facilities? 
c. What can be done differently to increase availability of essential medicines in Malawi’s 





6. Do you have any thoughts or additional information you would like to share with me? 
 

























APPENDIX D:  WRITTEN CONSENT FORM FOR QUALITATIVE RESEARCH 
 
University of North Carolina at Chapel Hill 
Consent to Participate in a Research Study 
Adult Participants  
Consent Form Version Date: March 9, 2018 
IRB Study # 17-2688 
Title of Study: AVAILABILITY OF ESSENTIAL MEDICINES IN MALAWI’S PUBLIC 
HEALTH FACILITIES: ENABLERS AND BARRIERS 
Principal Investigator: Ugbede Abu 
Principal Investigator Department: Health Policy and Management  
Principal Investigator Phone number: +265 -88-230-2501 
Principal Investigator Email Address: ugbede@live.unc.edu  
Faculty Advisor: Bruce Fried 
Faculty Advisor Contact Information: (919) 966-7355 
_________________________________________________________________ 
 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary. 
You may refuse to join, or you may withdraw your consent to be in the study, for any reason, 
without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future. You may not receive any direct benefit from being in the research study. There also 
may be risks to being in research studies.  
 
Details about this study are discussed below.  It is important that you understand this information 
so that you can make an informed choice about being in this research study.  
 
You will be given a copy of this consent form.  You should ask the researchers named above, or 
staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study? 
The purpose of this research study is to determine the availability of essential medicines in 
Malawi’s public health facilities, with focus on commonly used medicines HIV/AIDS, malaria, 
family planning and medicines used for treatment of common infections and diarrhea in children. 
Further, I like to learn about factors that contribute the availability (facilitators) or shortage 
(barriers) of these essential medicines in Malawi’s public health facilities. 




How many people will take part in this study? 
Between 8 and 12 organizations will be recruited to take part in the study and there will be at 
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least one person from each organization taking part in the study. 
 
How long will your part in this study last? 
This interview should take about 30 minutes. There is a chance that I will need to contact you for 
some follow up information but that would be brief and can be completed by telephone or email. 
 
What will happen if you take part in the study? 
If you agree to participate in the study, I will ask you some questions about the availability of 
essential medicines in Malawi’s public health facilities and how you and your organization 
contributing to the program.  I will ask you about some specific factors that are contributing 
(facilitators) or limiting (barriers) the availability of essential medicines in public health 
facilities, and actions that can be taken to increase availability.  
 
It will be completely confidential and any information that you provide will be released as a 
summary or combined into general themes. Your name will not be connected to your answers in 
any way.  Furthermore, this organization/facility will remain blinded and will not be listed by 
name but as an ‘organization X that offers service Y’. With your permission, I would like to 
record our interview. Digital audio files and transcripts will be confidentially destroyed at the 
end of the research study. 
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge. This research will benefit 
Government of Malawi and stakeholders who are working to increase availability of essential 
medicines in Malawi’s public health facilities. You will not benefit personally from being in this 
research study. 
 
What are the possible risks or discomforts involved from being in this study? 
There may be uncommon or previously unknown risks. You should report any problems to the 
researcher. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might affect 
your willingness to continue your participation.  
 
How will information about you be protected? 
I am taking multiple steps to ensure that your privacy and confidentiality will be protected.   
• Your name will only appear on the consent form.  All records will be kept in a locked 
location and electronic files will require a password.   
• I am the only person who will have access to individually identifiable information.  ID 
numbers will be used to identify the sites and the file that links them will require a 
password to access them. 
Participants will not be identified in any report or publication about this study.  Direct quotes 
will be used but not attributed to any person specifically. Although every effort will be made to 
keep research records private, there may be times when federal or state law requires the 
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disclosure of such records, including personal information.  This is very unlikely, but if 
disclosure is ever required, UNC-Chapel Hill will take steps allowable by law to protect the 
privacy of personal information.  In some cases, your information in this research study could be 
reviewed by representatives of the University, research sponsors, or government agencies (for 
example, Malawi’s National Health Sciences Research Committee) for purposes such as quality 
control or safety. 
o As soon as the audio recordings are transcribed and checked for accuracy, the audio files 
will be destroyed.  Transcripts will be kept in a folder requiring a password. Once the 
study has concluded and the dissertation has been accepted, the transcripts will be 
destroyed. 
Check the line that best matches your choice:  
 
_____ OK to record me during the study 
 
_____ Not OK to record me during the study 
 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty.  The investigator also has the 
right to stop your participation at any time. This could be because the entire study has been 
stopped. 
 
Will you receive anything for being in this study? 
You will not receive any compensation for being part of this study. 
 
Will it cost you anything to be in this study? 
It will not cost you anything other than your time to be in this study.  
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this research. If 
you have questions about the study, complaints, concerns, or if a research-related injury occurs, 
you should contact the researchers listed on the first page of this form. 
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact the Institutional Review Board 





Participant’s Agreement:  
 
I have read the information provided above.  I have asked all the questions I have at this time.  I 
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